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Abstract
Patients can react to a drug differently just by virtue of being different people, and this
between-patient variability in drug response is an obstacle to optimal treatment. Pharmacokinetic modelling offers one approach to studying drug response, often with covariate focused
dose adjustment criteria being reported along side pharmacokinetic modelling. However, excess variation in concentrations continues to be reported despite the use of these criteria, bringing into question optimal dosing strategies for some drugs. This thesis provides methods for
creating Bayesian pharmacokinetic models for two purposes: inference into the effects of covariates on concentrations and optimal sequential decision making for dose size. The thesis
addresses three objectives: To compare existing approaches to fitting Bayesian models with
recent advancements in pursuit of fitting population pharmacokinetic models, to develop a
framework for evaluating the benefits of collecting additional information for use in personalization, and to demonstrate how academic personalized medicine researchers can use all data
available to them to study effects of clinical variables on pharmacokinetics. To this end, the
thesis makes three research contributions. First, a simulation study demonstrating that inferences using popular inference methods in pharmacokinetic research can lead to different and
poorer calibrated decisions as compared to newer inference methods. The model presented in
the simulation study was developed using a specific parameterization achieved through nondimensionalization of the differential equation governing the mass transit of the drug and facilitates sampling with Hamiltonian Monte Carlo. Second, a unified framework for the development and simulation based evaluation of personalization based on pharmacokinetic modelling
combined with dynamic treatment regimes. Lastly, a demonstration of how investigators can
fit Bayesian pharmacokinetic models with the aim of accurate modelling of pharmacokinetics
and exploration of novel variables using data from heterogeneous sources. These contributions
provide methodologies do address two central goals of personalized medicine – identification
of factors driving between patient variability in drug response, and selection of an optimal dose
– and can enable a richer set of personalized decisions to be made.

Keywords: Bayesian Statistics, Pharmacokinetics, Hierarchical Model, Personalized Medicine
i

Lay Summary
Patients can react to a drug differently just by virtue of being different people, and this
between-patient variability in drug response is an obstacle to optimal treatment. Pharmacokinetic modelling offers one approach to studying drug response, often with covariate focused
dose adjustment criteria being reported along side pharmacokinetic modelling. However, excess variation in concentrations continues to be reported despite the use of these criteria, bringing into question optimal dosing strategies for some drugs. This thesis provides methods for
creating Bayesian pharmacokinetic models for two purposes: inference into the effects of covariates on concentrations and optimal sequential decision making for dose size. The thesis
addresses three objectives: To compare existing approaches to fitting Bayesian models with
recent advancements in pursuit of fitting population pharmacokinetic models, to develop a
framework for evaluating the benefits of collecting additional information for use in personalization, and to demonstrate how academic personalized medicine researchers can use all data
available to them to study effects of clinical variables on pharmacokinetics. To this end, the
thesis makes three research contributions. First, a simulation study demonstrating that inferences using popular inference methods in pharmacokinetic research can lead to different and
poorer calibrated decisions as compared to newer inference methods. The model presented in
the simulation study was developed using a specific parameterization achieved through nondimensionalization of the differential equation governing the mass transit of the drug and enables more reliable inference by sampling using Hamiltonian Monte Carlo as compared to
a standard parameterization. Second, a unified framework for the development and simulation based evaluation of personalization based on pharmacokinetic modelling combined with
dynamic treatment regimes. Lastly, a demonstration of how investigators can fit Bayesian pharmacokinetic models with the aim of accurate modelling of pharmacokinetics and exploration of
novel variables using data from heterogeneous sources. These contributions provide methodologies do address two central goals of personalized medicine – identification of factors driving
between patient variability in drug response, and selection of an optimal dose – and can enable
a richer set of personalized decisions to be made.
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Chapter 1
Introduction

1.1

Motivation

Patients can react to a drug differently just by virtue of being different people, even when those
patients match on relevant clinical variables. This between-patient variability in drug response
is an obstacle to optimal treatment, since some patients may experience heightened response
(possibly leading to toxicity) while others may experience lowered response (possibly leading
to inefficacy). Personalized medicine is a response to this variation. Morse and Kim identify
four goals for personalized medicine: 1) identify drugs for which between-patient variation is
a key issue for effective treatment, 2) address/identify factors driving this variation, 3) treat
the right patient with the right drug of the right amount at the right time, 4) and aid in the
prevention of adverse events associated with said drugs [70]. The goal of this thesis is to
develop methodology for identifying which factors are drivers of between patient variability in
service of better selecting the right dose for the right patient, and is thus aligned with goals 2
and 3.
The foundational health research discipline for this thesis is pharmacokinetics, which has
been described by Rosenbaum as concerning itself with the time course of drug concentrations
in the body [91]. Effective drug response requires adequate systemic exposure. Since drug
1

2
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concentration is a means of measuring drug exposure, an understanding which factors drive
variation in concentration can give insight into factors driving variation in response. To this
end, many pharmacokinetic modelling studies seek to identify clinical, genetic, and lifestyle
factors which are associated with changes in concentration. Some studies will provide dose
adjustment criteria based on the results of their modelling. These recommendations are personalized in so far as they identify sub-populations of patients which may see predictably
larger/smaller concentrations as a function of standard doses. However, there exists additional
concentration variability beyond that observed in clinical trials for some drugs [106], raising
questions about optimal dosing for these drugs. The discovery of this excess variation in applied settings motivates the “fine tuning” or “tailoring” of the pharmacokinetic modelling done
in previous studies for better titration in the population of interest.
One approach to tailoring or fine tuning previous modelling is through the use of Bayesian
statistics. In the Bayesian framework, a prior distribution of plausible parameter values is
specified before seeing data. Once data is collected then the model can be “updated” with
the data. The prior distribution allows researchers to start with an existing model they think
appropriately describes their population of interest, and sequentially update or “fine tune” the
model as additional data is collected. This workflow of starting with an initial belief about the
patient, collecting data, and updating said belief is roughly reflective of how dose titration for
drugs like warfarin are performed.
While the Bayesian framework is one possible formalization of the process of updating
beliefs about pharmacokinetics when observing data from dose titration, the framework of dynamic treatment regimes is one possible formalization for optimizing the sequential process of
selecting the doses for titration. Chakraborty and Murphy describe dynamic treatment regimes
as “one way to operationalize a clinical decision support system” [25], that is to say dynamic
treatment regimes are a formalization of the sequential decisions made about treating patients.
Since personalized medicine can be conceived as a set of sequential decisions (on how best to
treat a patient based on observations made from a titration process), dynamic treatment regimes
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offer an enticing set of tools for personalized medicine and see continued use in the field. Because decisions in personalized medicine can be made on the basis of concentrations (be they
too high or too low to elicit a desired response), the incorporation of pharmacokinetic models into dynamic treatment regimes for purposes of sequentially optimal dose titration offers a
synergy of two frameworks important to personalized medicine.
This thesis provides methods for creating Bayesian pharmacokinetic models for two purposes: inference into the effects of covariates on pharmacokinetic parameters and thereby concentrations, as well as use for these models in sequential decisions on dose size. Bayesian
statistics is the formalism adopted so as to incorporate and directly build upon prior information from other pharmacokinetic modelling efforts. These models can be used in service of
the second goal of personalized medicine, identification of factors driving variation in drug response. The models will be directly incorporated into a sequential decision making framework
thereby addressing questions pertaining to the third goal of personalized medicine, optimal
dosing.

1.2

Objectives

I address three objectives motivated by the desire to identify sources of between patient variability and account for these in downstream decisions on drug dosing:
1) To compare and contrast existing approaches to fitting Bayesian models with recent advancements in the pursuit of fitting population pharmacokinetic models.
2) To develop a framework for evaluating the benefits of collecting additional information
against the additional burden posed on the patient.
3) To demonstrate how personalized medicine researchers in academic centres can use all data
available to them, even if those data do not come from tightly controlled studies, to study
effects of clinical variables on pharmacokinetics while also exploring new variables which

4
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may explain additional variation.

1.3

Research Contributions

The research contributions of this thesis are as follows:
1. A one-compartment pharmacokinetic model with first order elimination written in an
open source probabilistic programming language. To create this model, I developed a
specific parameterization, achieved through non-dimensionalization of the differential
equation governing the kinetics, which enables more reliable inference by sampling using Hamiltonian Monte Carlo compared to a standard parameterization. Lastly, I present
a simulation study demonstrating that inferences made using a popular inference method
in pharmacokinetic research (Maximum A Posteriori) leads to different and poorer calibrated decisions as compared to inference methods proposed more recently that are
enabled by the new parameterization.
2. A unified framework for the development and simulation-based evaluation of personalization based on pharmacokinetic modelling that is combined with dynamic treatment
regimes. I demonstrate how the framework can be applied with a case study, considering
six modes of personalization, each of which differ in the amount of information collected
from and burden imposed on the patient (in terms of adhering to additional measurement
requirements). The knowledge created by the framework can be integrated into a system
level decision-making framework, such as Know4Go [65].
3. A demonstration of how investigators can fit Bayesian pharmacokinetic models with aim
of accurate modelling of pharmacokinetics and exploration of novel variables. Importantly, this approach demonstrates how to use all data available to investigators. The data
I use come from two very different sources: one from a well controlled clinical study
with strict inclusion/exclusion criteria and the other from a personalized medicine clinic
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in which subjects are observed only once. In particular, I note that when some studies
collect multiple observations from the same patient and others collect only a single sample, traditional modelling approaches which concatenate all data violate the assumption
of exchangeability. In response, I offer a reparameterization for which the exchangeability assumption is more defensible. Lastly, I demonstrate how sparsity inducing priors
can be applied to new variables in order to explore how those variables may effect pharmacokinetics, and demonstrate the efficacy of the method in a simulation study. I show
that when data come from two different types of studies, like the ones mentioned above,
then the bias imparted from the sparsity inducing prior can be sufficiently small so as to
be acceptable (especially in light of the exploratory nature of the problem).

1.4

Thesis Organization

This thesis is written with an integrated-article format. Chapter 2 provides necessary background on concepts and terms that are needed to understand the body of the work. Chapter 3
provides a literature review of recent advances in the fields of Bayesian statistics, sequential decision making, and pharmacokinetics, providing context for the three articles to follow.
Chapters 4, 5, and 6 include the integrated articles which address objective 1 — 3 respectively. Chapter 7 concludes the thesis with an overarching discussion and examines possible
subsequent areas of investigation. Any appendices are included at the end of each integrated
article, and may contain supporting materials such as extra information on methods, additional
exposition for models, and additional visualizations. Due to the nature of the integrated article
format, there is some repetition between introductory sessions.

Chapter 2
Background
In this chapter, I describe the necessary background for the research presented in this thesis, covering four key topics: differential equations, Bayesian statistics, pharmacokinetics, and
dynamic treatment regimes. Much of this thesis concerns drug concentrations and decisions
therein which optimize the concentrations subject to some criteria. Pharmacokinetics concerns
itself with the absorption, distribution, metabolization, and elimination of a drug from the body,
making it an important framework to use when reasoning about drug concentrations. The models used in pharmacokinetics are written in terms of differential equations, hence a working
knowledge of differential equations and their properties is needed in order to reason about the
pharmacokinetic models. Bayesian statistics is used to combine prior information of pharmacokinetic phenomena with data in order to perform inference on the pharmacokinetic model
parameters, as well as to simulate new data and perform model validation. Dynamic treatment
regimes are a formalization of sequential decision making. Since personalized medicine involves sequential decisions (on say the next dose size to prescribe to a patient, as an example),
the dynamic treatment regime framework will be relevant to formally reason about decision
making.
The focus of the first section is differential equations, specifically first order separable equations and the Laplace Transform. I briefly discuss conditions under which a differential equa6
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tion has a unique solution, as well as techniques for qualitative analysis of a system’s dynamics
under families of equivalent parameterizations. Then, I discuss Bayesian statistics, touching
on model design, model checking, and model fitting. In the next section I discuss population
pharmacokinetic models, touching on their derivation through differential equations as well
as extensions to include multiple doses. I conclude this chapter with a treatment of dynamic
treatment regimes and estimation of an optimal policy through Q learning.

2.1
2.1.1

Differential Equations
Initial Value Problems, Existence, and Uniqueness

A differential equation relates an unknown function y(t) to its derivative y′ (t) through a known
function f (t, y(t), θ) [107]. Here, the function f may depend on parameters, θ which can be
known exactly or require estimation from data. For economy of thought, dependence of f
on θ is implied though not always explicitly stated. A differential equation is called ordinary
(referred to as an ODE) if y is a function of a single scalar variable t, which for the purposes of
this thesis can be considered to be time. An ODE together with an initial condition – a value
of y at some point t0 in its domain – is referred to as an initial value problem (or sometimes an
IVP),

dy(t)
= f (t, y(t), θ) y(t0 ) = y0
dt

(2.1)

Here, y(t) could represent the concentration of a drug in the blood as a function of time, t0
could be some time after the drug was ingested, and y0 could be the concentration at t0 . If
the function f can be written as f (t, y(t)) = Q(t) − I(t)y(t), then we call the ODE a first order
linear ordinary differential equation. Often, the differential equation is written with all terms
involving y(t) on one side, such as dy/dt + I(t)y(t) = Q(t), in which case Q(t) is referred to
as the forcing function. First order linear equations are of particular interest, as they are easily
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solved analytically and are sufficient to model pharmacokinetic under certain assumptions of
how the body acts on the drug.
Not every IVP which can be written down has a solution, but there do exist general criteria for existence and uniqueness to a solution for equation (2.1). The only requirements are
that a) f be continuous in t, and b) f be Lipschitz continuous in y. Under these conditions,
Picard–Lindelöf theorem [107] guarantees a unique solution exists.
Theorem 2.1.1 (Picard–Lindelöf Theorem) Let D ⊆ R×Rn be a closed rectangle with (t0 , y0 ) ∈
D, and let f : D → Rn be a function that is continuous in t and Lipschitz continuous in y. Then,
there exists some ϵ > 0 such that equation (2.1) has a unique solution y(t) in an interval centred
at t0 with radius ϵ.
This thesis is mainly concerned with functions f which are continuous in y. If a function is
continuous in a variable, then it is also Lipschitz continuous in that variable. Hence, all IVPs
for which we concern ourselves with have a unique solution.

2.1.2

Solutions to First Order Linear Equations

So long as the function f (t, y(t)) = Q(t)−I(t)y(t) satisfies the conditions for the Picard–Lindelöf
theorem, then a solution exists and it is unique. Assuming Q(t) and I(t) are written in terms
of analytic functions, then the solution to equation (2.1) can be written out analytically. Let
R
P(t) = exp( I(t) dt) be an integrating factor. Multiplying both sides of the ODE by P(t) yields

P(t)

dy
+ I(t)y(t) = Q(t)
dt

(2.2)

dy
+ P(t)I(t)y(t) = P(t)Q(t)
dt

(2.3)

The form of P(t) implies P′ (t) = P(t)I(t), and so the left hand side of the differential equation
looks as if it is the result of the product rule
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dy
d
P(t)y(t) = P(t) + P(t)I(t)y(t)
dt
dt

(2.4)

= P(t)Q(t)

(2.5)

Integrating and division by P(t) (which is possible since P(t) > 0 by construction) yields the
solution to the differential equation
R
y(t) =

Q(t)P(t) dt
P(t)

,

(2.6)

wherein the constant of integration from the numerator is determined by using the initial condition. The general takeaway is that so long as f satisfies the conditions for the Picard–Lindelöf
theorem, and Q(t) and I(t) are not sufficiently complicated so as to prevent integration, then the
solution to equation (2.1) can be written down exactly.

2.1.3

Non-dimensionalization

Differential equations representing physical systems can often have several parameters, and the
qualitative behaviour for the solution can be similar across many different families of parameterizations. A technique used by applied mathematicians to study the qualitative behaviour
of a differential equation is known as non-dimensionalization [50, p. 25]. The technique involves rescaling the solution y(t) (the units of which depend on what is being modelled) and
the time variable t (which could be measured in seconds, hours, minutes, etc.) to be unitless.
Let a , 0 be measured in the same units as t and let b , 0 be measured in the same units as
y. Then, we can define non-dimensional variables τ and x so that t = aτ and y = bx. The
non-dimensionalization of the differential equation dy/dt = f (t, y(t)) in terms of τ and x is
obtained by applications of differentiation rules

10

Chapter 2. Background


d  d
y(t) =
bx(τ)
dt
dt
dx(τ) dτ
=b
dτ dt
b dx(τ)
=
a dτ

(2.7)
(2.8)
(2.9)

which yields dx/dτ = a/b f (aτ, bx(τ)). The approach is similar to normalization in statistics
(i.e. subtracting the mean and dividing by the standard deviation). The re-scaling allows one
to examine families equivalently parameterized differential equations, giving insight into the
characteristic dynamics of the system. Non-dimensionalizing a differential equation will important when defining prior distributions over parameters in Bayesian inference.

2.1.4

The Laplace Transform and Discontinuous Forcing Functions

Under the conditions that a function f is piecewise continuous on an interval 0 ≤ t ≤ A for
any positive A, and that | f (t)| ≤ K exp(at) when M ≤ t for real constants 0 < K, a, M, then the
integral
Z

∞

f (t)e−st dt
0

exists and is called The Laplace Transform, denoted L { f } (s) [15, p. 317].
The Laplace Transform can be used to turn a first order linear differential equation into an algebraic equation due to the property that L { f ′ } (s) = sL { f } (s)− f (0), which can be demonstrated
by applying integration by parts. The algebraic equation can then be solved and inverted from
s space to t space. The Laplace Transform can be used to solve differential equations with
discontinuous forcing functions. These differential equations take the form

dy
+ I(t)y(t) = Q1 (t) + H(t)Q2 (t) .
dt

(2.10)
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Here, H(t) is a Heaviside step function







1
H(t) = 





0

t>0
(2.11)
else

When t < 0, Q2 (t) is essentially “turned off” and its effect on the dynamics of y is 0. When
t > 0, the effect is then “turned on”. As an example, we consider a differential equation which
will be of use in the remainder of this thesis

dy
+ αy(t) = exp(−t) + H(t − t1 ) exp(−(t − t1 ))
dt

y(0) = 0 .

(2.12)

Here, the dynamics undergo a force of exp(−(t − t1 )) when 0 < t1 ≤ t. The Laplace Transform
can be used on both sides (leveraging tables of Laplace Transforms for common functions [15])
of the differential equation to yield

sL {y} (s) − y(0) + αL {y} (s) =

1 + exp(−st1 )
.
1+s

The equation is now algebraic in terms of L {y} (s). Solving for L {y} (s) yields

L {y} (s) =

1 + exp(−st1 ) 1
,
1+s
s+α

(2.13)

and applying the inverse Laplace Transform yields


y(t) =




exp(−t) − exp(−αt) + H(t − t1 ) exp(−(t − t1 )) − exp(−α(t − t1 ))
α−1

(2.14)

Because the two forcing functions in the differential equation were identical (one was just
shifted t1 units to the right) the solution to the differential equation is comprised of the same
two functions, one of which is shifted t1 units to the right. The Laplace Transform will be of
particular use when deriving solutions to differential equations which describe mass transit of
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a drug through the blood. In these applications, multiple doses are taken through time and can
be represented as discontinuous forcing functions using Heaviside functions. When a patient
takes a dose of a drug, the effect of that dose on the system dynamics is “turned on” at the time
of ingestion. Additionally, because the Laplace Transform is a linear operator, we can consider
arbitrarily many discontinuous forcing functions. Pharmacokinetic models where patients take
multiple doses of a drug can be expressed as first order linear differential equations with discontinuous forcing functions, and so the Laplace Transform will be an important technique for
solving these differential equations exactly.

2.2

Bayesian Statistics

In this section, I introduce some key concepts of Bayesian statistics to be used in the remainder of the thesis. I begin by briefly reviewing how Bayesianism differs from Frequentism in
philosophy. I then introduce Bayes nets as a tool for visualizing the factorization of the joint
distribution. Finally, I discuss model diagnostics and MCMC computation for Bayesian inference.

2.2.1

The Bayesian Philosophy on Probability

Gelman and colleagues have described Frequentist interpretations of probability as the “ relative frequency obtained in a long sequence of [events], assumed to be performed in an identical
manner, physically independent of one another ” [38, p. 12]. Frequentism has been contrasted
against Bayesianism, which has sometimes been said to view probability as a subjective form
of uncertainty quantification [38].
Core to Bayesian statistics is Bayes’ rule [38, p. 7]

p(θ|y) ∝ p(y|θ)p(θ) .

(2.15)

Here, θ and y can refer to events (e.g. p(θ|y) could refer to the probability of having a disease
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given you test positive), but in the remainder of this thesis θ will refer to model parameters,
and y to observed data. The distributions p(θ|y), p(y|θ), and p(θ) are referred to as the posterior, the likelihood, and the prior respectively. Since the result of Bayes’ rule is a probability
distribution (i.e. the probability of the parameters conditioned on the data), inferences resulting from a Bayesian analysis are expressed as probabilistic statements. Bayesian modelling
begins by specifying a full probability model for the phenomenon. A likelihood for the data
generating process is specified, and prior knowledge about the parameters is codified in terms
of a probability distribution (i.e. the prior). Conditioning on the observed data is performed,
and the posterior is calculated and interpreted. Finally, the resulting model is evaluated and the
implications of the resulting posterior are assessed.

2.2.2

Bayesian Networks

Bayesian models describe the full joint distribution over all variables and parameters of interest, and can become quite complex. Bayesian networks (Bayes nets) can be used to simplify
model description by dividing the model into components and then describing the relationships
between those components. A Bayes net is a directed acyclic graph which represents a factorization of the joint probability distribution of the model. The nodes of the graph denote random
variables (which include parameters), while the edges denote dependence of the child node on
the parent node [14].
Shown in figure 2.1 is an example of a Bayes net for Gelman’s rat tumour example in [38].
A total of N = 71 experiments on lab rats have been conducted in the past to assess the risk
of developing endometrial stromyl polyps. A rat can either develop the endometrial stromal
polyp, or not develop the endometrial stromyl polyp, so the number of rats which develop the
polyp, yi , is modelled as binomial. Each of the 71 previous experiments is modelled as having
it’s own risk of developing the polyp, θi for i = 1, . . . , N, which we postulate are drawn from a
beta distribution with parameters α and β.
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Algebraically, the model would be written as
[α, β]T ∼ p(α, β)
θi |α, β ∼ Beta(α, β) i = 1 . . . N
yi |θi , α, β ∼ Binomial(θi ; ni ) i = 1 . . . N

Here, p(α, β) is the prior for the parameters of the beta distribution, and ni is the number of
rats in the ith experiment. This same model is written as a Bayes net in figure 2.1. The node
containing α and β is the parent of θ, indicating that θ depends on α and β, and y is the child
of θ, indicating that y depends on θ. It is worth noting that if the parent nodes are known, then
the child nodes are independent of all other nodes in the model. The rectangle surrounding θ
and y signifies that there are N such copies of these random variables which are considered
exchangeable conditioned on the parent nodes. Instead of explicitly writing out all N = 71
of these random variables, we instead place them in what is known as a “plate”, and indicate
in the bottom corner how many replicates there are. Bayes nets make it very easy to write
out the posterior distribution of the parameters. We simply follow the net from the bottom up,
conditioning each node on it’s parent nodes. The posterior for this model is then

p(α, β, θ|y) ∝ p(α, β)

N
Y

p(θi |α, β)p(yi |θi )

i=1

Note that while the Bayes net describes the dependence structure of the model, it does not
specify the forms of the individual conditional distributions; these must also be provided to
fully specify the model.

2.2.3

Model Assessment

Once a model is specified, and the posterior for the parameters obtained, the model fit, not only
to the data but also to the practitioner’s substantive knowledge, must be assessed.
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y
N

Figure 2.1: Bayes net for hierarchical binomial model. Note here that nodes with shading
correspond to observed data, while nodes without shading are latent, or unobserved.

Since the result of a Bayesian analysis is the posterior distribution over the model parameters
given the observed data, data can be simulated from the inferred data generating process. Let
y be observed data, and θ be a vector of parameters for the model. Denote ỹ as replicated
data from the data generating process, or as Gelman writes, “data that we would have seen
tomorrow if the experiment that generated y today were replicated with the same model and
the same value of θ that produced the observed data” [38, page 145]. Then the distribution of
the replicated data conditioned on the observed data is
p(ỹ|y) =

Z

p(ỹ|θ)p(θ|y) dθ .

(2.16)

The distribution in equation (2.16) is called the posterior predictive distribution. If the model
fits the data well, then observed data should look plausible under the posterior predictive distribution. In a posterior predictive check, simulated data sets are generated from equation (2.16)
and are compared to the observed data. Any systematic differences between observed and
simulated may point to areas in which the model can be improved.
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2.2.4

Maximum A Posteriori (MAP) and The Laplace Approximation to
the Posterior

The integrals in Bayesian statistics required to evaluate probabilities quickly become intractable
even when considering simple models. Point estimates for model parameters can be obtained
by maximizing the log posterior density. If the posterior is p(θ|y), then a point estimate for θ is

n
o
θMAP = arg max log p(θ|y)
θ∈R p

n
o
= arg max log p(y|θ) + log p(θ)
θ∈R p

This approach is known as Maximum A Posteriori or MAP for short [72]. The point estimate
θMAP corresponds to the mode of the posterior distribution. If the prior p(θ) places uniform
probability over all values of θ then the MAP estimate corresponds to the maximum likelihood
estimate. When the prior is not uniform over θ, then the prior acts as a regularizing term on the
maximum likelihood estimate, with more informative priors offering more regularization.
The MAP estimate is attractive because of its speed (as compared to other forms of estimation for Bayesian models discussed below). However, it is only a point estimate rather than
a distribution. To further approximate the posterior distribution, a Laplace Approximation to
the posterior can be made by performing a quadratic approximation to the log posterior density
[72]. The result of this technique is that the posterior is locally modelled as Gaussian

p(θ|y) ≈ Normal(θMAP , Λ−1 ) .
Here, Λ is the estimated precision matrix, obtained by computing the Hessian of the negative
log posterior at the MAP estimate.
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Markov Chain Monte Carlo & Modern Methods

Computational methods have been developed that can sample from the posterior distribution
without having to know the exact analytical form of the posterior distribution. The suite of
computational methods for sampling from the posterior are called Markov Chain Monte Carlo
(MCMC) methods. These methods simulate Markov chains whose limiting distribution is the
posterior distribution [61]. The earliest MCMC methods for drawing samples from the posterior are The Metropolis-Hastings Algorithm and Gibbs Sampling [38, 67]. Recently however,
these algorithms have given way to more efficient algorithms, known as Hamiltonian Monte
Carlo (HMC) methods. In these methods, the posterior is idealized as a high dimensional surface in the model’s parameter space on which a particle of mass m rolls after being given a
random position and momentum. The geometry of the surface influences the movement of the
particle, and thus influences the samples obtained. The theory for HMC is quite dense and so I
refer interested readers to the following resources [38, 61, 67, 73, 48, 10] for further explanation. Because of HMC’s complexity and requisite background theory on Hamilonian dynamics
and measure theory, I will consider HMC a black box for the purposes of this thesis.
All of these sampling methods result in a user specified number of sequences of samples of
size M, often simply referred to as chains. After obtaining M samples, and preferably omitting
the first K, the remaining M −K samples are treated as iid draws from the posterior distribution.
The chains can then be used to estimate expectations of model parameters, uncertainty in those
estimates, and make predictions.

2.2.6

Diagnostics for Hamiltonian Monte Carlo

In MCMC and HMC, several chains are usually initialized and allowed to run for sufficiently
long to as to (hopefully) arrive at their stationary distribution. If geometric ergodicity holds,
then all chains should arrive at the same stationary distribution, and thus be exploring the
b measures how well the chains are
same space. The Gelman-Rubin diagnostic, denoted R,
exploring the space by comparing the within chain variance to the between chain variance
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b indicates a problem with the chains, and inference should not be
[38]. In practice, 1.05 < R
made from the samples drawn [3].
Another diagnostic is the effective sample size, neff . Theories of convergence of functions of
random variables that assume independence are inappropriate as the samples from the Markov
chains are correlated. Effective sample size is a heuristic used to measure how close the samples
are to being independent. Effective sample size is defined as
neff =

M−K
X
.
1+2
ρ(k)
k

Here M − K is the length of the chain and ρ(k) is the lag-k within chain correlation [38, 55]. If
the chains are autocorrelated, then neff < M − K, and if the chains are completely independent
neff = M − K. If chains are highly correlated, then neff ≪ M − K, and inferences made from
the samples should be avoided because of the bias the correlation would impart.

2.3

Pharmacokinetics

Pharmacokinetics is the the study of drug absorption, distribution, metabolism, and elimination
of a drug [91]. Less formally, it is the study of how drugs enter the body, distribute throughout
the body, and leave the body, as well as the rates at which these phenomena occur. Generally, modelling the time course of drug concentrations in various body compartments (e.g. the
blood) is of central interest. Understanding the time course of concentrations is important to
pharmaceutical therapy as concentrations which are too high can lead to toxicity, while concentrations which are too low can lead to ineffectiveness. Pharmacokinetic models are thus a
tool to reason about the time course of drug concentrations, and in turn the drug’s effectiveness
or toxicity.
In this section, I review the basics of pharmacokinetic modelling and introduce the central pharmacokinetic model used in this research, describing the model using a differential
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equation. Population pharmacokinetic models are discussed as a generalization of the one
compartment pharmacokinetic model.

2.3.1

A One Compartment Pharmacokinetic Model

In pharmacokinetic modelling, compartmental models are used to model the time course of
concentrations [91]. These models posit that the body (or relevant organs/systems of the body)
is comprised of compartments from which the drug can flow out, and to which the drug can
flow in. The rates at which the drug can enter and exit each compartment are specified, and
a differential equation for each compartment can be written down and solved using methods
outlined in section 2.1.
An example of such a model which can be used for orally-administered drugs is the one–
compartment pharmacokinetic model with first order elimination. The model assumes the
following [119]:
• The patient orally ingests a dose of size D in units milligrams.
• The concentration of drug in all parts of the body (blood, plasma, liver, brain etc) are the
same.
• The rate of drug absorption from the gut into the blood plasma (C) is proportional to the
amount of drug in the gut and that the proportionality constant is ka , in units hours−1 .
• The rate of elimination from the blood plasma is proportional to the amount of drug in
the plasma compartment with proportionality constant ke , in units hours−1 .
• The apparent volume of the body compartment is V, measured in litres.
• The fraction of the administered dose that reaches the systemic circulation is the drug’s
bioavailability, F.
• At the time of ingestion, there is 0 drug in the blood plasma.
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Let t be time since ingestion of the drug, and assume that ke < ka for identifiability. The

differential equation governing the mass transit of drug in/out of the C compartment is then
dC(t)/dt = ka FD exp(−ka t) − keC(t)

(2.17)

with the initial condition C(0) = 0, and is a first order linear differential equation. The concentration of the drug in the C compartment can be obtained by dividing C(t) by the volume of the
C compartment, V. Using the technique of integrating factors, the differential equation can be
solved to yield

C(t) =


FD ka 
exp(−ka t) − exp(−ke t) .
V ke − ka

(2.18)

In the remainder of this thesis, equation (2.18) will be parameterized in terms of the clearance Cl = V · ke rather than in terms of volume due to more prior information being available
about the clearance rate of certain drugs as opposed to the volume of patients. The resulting
parameterization is

C(t) =

2.3.2


FD ke ka  −ka t
e − e−kt .
Cl ke − ka

(2.19)

Multiple Doses

To extend equation (2.17) to account for multiple doses, Heaviside step functions can be applied. The forcing function in equation (2.17) is ka FD exp(−ka t). If a patient were to take the
same dose at time t1 , then the resulting ODE would be
dC
= ka FD exp(−ka t) − keC(t) + H(t − t1 )ka FD exp(−ka (t − t1 )) .
dt

(2.20)

Here, H(t) is the Heaviside step function. This ODE can be solved by applying The Laplace
Transform. The solution is
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C(t) = C0 (t) + H(t − t1 )C0 (t − t1 ) ,

FD ka 
C0 (t) =
exp(−ka t) − exp(−ke t)
V ke − ka
This approach can be extended to arbitrarily many doses by the same approach. Additional
extensions, such as having multiple different dose sizes, can be applied in the same way.

2.3.3

Population Pharmacokinetic Models

Different patients may have different pharmacokinetics just by virtue of being different people
(even if they match identically on important clinical and genetic covariates). To understand the
between subject variability in pharmacokientics, a population pharmacokinetic model can be
constructed. These models make the assumption that some or all of the parameters in equation (2.19) (or some other pharmacokinetic model for that matter) are themselves random variables, which have some population level mean and variance which requires estimation [78].
As an example, the clearance rate for the ith patient in the population, Cli , can be considered as
a draw from some population level distribution, Cli ∼ P(ψ), where P is some distribution with
suitable support for the modelled parameter and ψ are parameters of this distribution. This
approach is similar to non-linear mixed effect modelling; non-linear because the concentration function is non-linear in the pharmacokinetic parameters, and mixed-effects because the
parameters are free to vary between patients [78, 71].
Many software packages exist to fit population pharmacokinetic models. Notable examples
include NONMEM [6] and Monolix [2] (both of which happen to be propriatary software) and
Pumas [85] which is freely available and accessed through the Julia language (which is also
free), among others. Each implementation shares similar techniques for parameter estimation,
namely by optimizing the negative log likelihood (which is sometimes called the Objective
Function or OFV) [6, 71, 7], as well as approximation methods for computing the marginal
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likelihood. Several approximation techniques are made available to users, but the differences
in resulting estimates from these methods can sometimes be substantial [71].

2.4

Dynamic Treatment Regimes and Q Learning

In the following subsections, I present background material on dynamic treatment regimes,
which are used to develop optimal decision-making models. The framework of dynamic treatment regimes can be used to develop optimal sequential decision making models. I will use
this framework to demonstrate how Bayesian pharmacokinetic models based on differential
equations can be used for sequential decision support.

2.4.1

Dynamic Treatment Regimes

A dynamic treatment regime (DTR) is a sequence of decision rules for adapting a treatment
plan to the time-varying state of an individual subject [24]. In DTRs, and their cousin topic
in computer science reinforcement learning, an agent (often thought of as a robot in reinforcement learning, but within medicine sometimes thought of as a physician’s computerized
decision support system) interacts with a system a number of times. In the terms of DTRs
and reinforcement learning, each interaction with the system is considered a stage. At each
stage, the agent receives an observation of the system and then determines an action to take.
This action will result in an observed reward which is followed by a new observation of the
system after it has been impacted by the action. This cycle of observation, action, reward then
repeats, with the agent aiming to take actions which yield the largest total reward. For more on
reinforcement learning and DTRs, see [28, 24].

2.4.2

Trajectories

The data generated by the cycle of observation, action, and reward from the initial action
to the final reward is called a trajectory. Formally, define a stage to be a triple containing

2.4. Dynamic Treatment Regimes and Q Learning

23

an observation, chosen action, and resulting reward. Let Oi denote an observation at the ith
stage, Ai be the action at the ith stage, and Yi denote the reward at the ith stage, in capital
letters when considering the observation, action, and reward as random variables. Following notation by Chakraborty and Moodie [24], define the history of the system at stage j to
be H j = (O1 , A1 , O2 , A2 , · · · , O j−1 , A j−1 , O j ). The reward at stage j can be thought of as a
function of the system’s history, the action taken, and possibly the new state of the system
Y j = Y j (H j , A j , O j+1 ). As is explained in the next section, the expected sum of rewards from
each stage under different actions is of primary interest in DTRs. Since the reward is a random
variable, the sum of rewards is also a random variable. Refer to the expectation of the sum
of rewards as the value, and refer to the observed sum of rewards as the return. Importantly,
rewards reflect the immediate desirability of single action, where as value reflects longer term
desirability of a sequence of actions.

2.4.3

Policies, Value Functions, and Q-Learning

Let K be the number of stages in a DTR. A policy d = (d1 , · · · , dK ) is a vector of decision rules
each of which take as input the system’s history and output an action to take. Each decision
rule is a function d j : H j → A j where H j and A j are the history and action spaces at stage j
respectively. The stage j value function for a decision rule d is the expected sum of rewards the
agent would receive starting from history h j (here in lower case since it is an observed quantity)
if it chose actions according to d for every action thereafter. The stage j value function is

V dj (h j )

 K

X

= Ed  Yk (Hk , Ak , Ok+1 ) H j = h j  .

(2.21)

k= j

Here, the expectation is over the distribution of trajectories. Since the value is expected the
sum of rewards, the stage j value function can be decomposed into the expectation of reward
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at stage j plus the stage j + 1 value function [24]
h
i
V dj (h j ) = Ed Y j (H j , A j , O j+1 ) + V dj+1 (H j+1 )|H j = h j .

(2.22)

The optimal stage j value function is the value function under a policy which yields maximal
value

n
o
d
V opt
(h
)
=
max
V
(h
)
.
j
j
j
j
d∈D

(2.23)

Here, D is the space of policies. Estimating a policy that maximizes value can be achieved by
estimating the optimal Q function [24]. The optimal Q function at stage j is a function of the
system’s history h j and a proposed action a j ,
h
i
opt
Qopt
(h
,
a
)
=
E
Y
(H
,
A
,
O
)
+
V
(H
)|H
=
h
,
A
=
a
j
j
j
j
j
j+1
j+1
j
j
j
j .
j
j+1

(2.24)

Note that the optimal Q function has similar form and interpretation to the optimal value function (namely, it is the expected return —the value —starting at stage j with history h j but with
the added condition that we take action a j now and then follow the optimal policy thereafter).
Given the optimal Q function, an optimal policy is given by
n opt
o
(h
)
=
arg
max
(h
,
a)
.
dopt
Q
j
j
j
j
a∈A
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(2.25)

Similarity to Statistical Decision Theory

Dynamic treatment regimes and reinforcement learning concern learning a policy to obtain
maximal value. Thus, they are concerned with multi-stage decision making under uncertainty.
These frameworks bear a resemblance to statistical decision theory, in which a single decision
is to be made under uncertainty. Following [9], there exists an unknown quantity or quantities
θ ∈ Θ called the state of nature which affects the decision process and which may require
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estimation using data, X . Associated with every state of nature and decision (more commonly
called an action), a, is an associated loss incurred, L(θ, a). From a Bayesian perspective, the
goal is then to determine the action, aopt which minimizes the Bayesian expected loss

aopt = arg min {E π [L(θ, a)]}
Z a∈A
E π [L(θ, a)] =
L(θ, a)π(θ) dθ

(2.26)
(2.27)

Θ

Here π is the believed probability distribution of θ at the time of decision making. If data
and a model are available, then π could be the posterior distribution of θ after conditioning
the model on data. Similar approaches exist when using a Frequentist perspective, but they
will not be discussed here because this thesis is primarily concerned with Bayesian models.
For more information on Frequentist approaches to decision making under uncertainty see [9].
Assuming a Bayesian perspective again, minimizing the expected Bayesian loss in statistical
decision theory is equivalent to minimizing the negative reward in a single stage DTR.

2.4.5

G-Estimation for Estimating Optimal Policies

Several other techniques can be used to estimate the optimal policy, including G-estimation
[89]. Where as Q-learning maximizes the value function (which can be thought of as the mean
outcome), G-estimation is used to optimize the mean difference in outcomes under two actions
conditional on history. The mean difference is expressed using the blip function [88]. Again,
following notation from Chakraborty and Moodie, the blip function is
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(2.28)

and is interpreted as the difference in rewards when taking action a j at stage j and taking
action drej f at stage j (here, drej f can be considered the action taken from some reference or
control policy) having make the same sequences of actions for the first j − 1 stages ā j−1 , and
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then following the optimal policy from stage j + 1 onward. Important to G-estimation are
the a) no unmeasured confounders , and b) stable unit treatment value assumption (i.e. that
a subject’s outcome is not influenced by other subjects’ treatment allocation) [25]. The main
benefit is that under these aforementioned assumptions, estimates from G-estimation are doubly
robust. This means that estimates are consistent if either the blip function or the intervention
model is correctly specified [87]. Though G-estimation is a powerful and general technique,
we choose to use Q-learning in the proceeding work because we will make the assumption that
the data generating process (as modelled by Bayesian pharmacokinetic models) is sufficiently
well understood so as to not greatly benefit from G-estimation methods.

Chapter 3
Literature Review
This chapter reviews the historical development of three areas of research central to the thesis:
Sampling methods for Bayesian models, dynamic treatment regimes using PK/PD models, and
methodology for “pooling” or data aggregation across studies. For each area, it also identifies
the most current relevant work and research gaps which are addressed by this thesis.

3.1

Bayesian Inference Methods in Personalized Medicine

Statistical applications of HMC began with Neal’s work on neural network models in 1996
[74, 17], though the method was initially used to model systems of idealized molecules [30].
The method saw some statistical applications thereafter and appearances in statistical textbooks
(as an example, Irshwaran wrote about the use of HMC to fit Bayesian generalized linear
models with canonical link as well as feed forward neural networks in 1999 [52], MacKay [64,
Chapter 30] and Bishop [14, Chapter 11] included the method in their 2003 and 2006 books
respectively though Bishop included the technique under its original title of Hybrid Monte
Carlo, and Schmidt used HMC in pursuit of a non-parametric Bayesian approach to non-linear
regression via function factorization [95]). Neal noted the technique still seemed to be “under
appreciated” by statisticians in his 2011 review of the method in The Handbook of Markov
Chain Monte Carlo [17, Chapter 5], suggesting HMC was not as widely used as it could have
27
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potentially been.
Work on Stan, a probabilistic programming language which sees continued use today in
both academic and industrial work [13], began in 2010 [100] after researchers failed to fit the
types of models they wanted to fit using existing MCMC software tools like JAGS [83] and
BUGS [63]. The inability of existing samplers to converge to the appropriate posterior in a
reasonable time (if they converged at all) spurred these researchers to write an implementation
of HMC, and this would eventually become the Stan programming language [100]. Stan’s
first stable release in 2012 [100] implemented an improved HMC sampler known as the No-UTurn Sampler (or NUTS for short) [100, 48], as well as additional improvements beyond those
mentioned in the NUTS paper [100]. The result was a centralized, open source, and efficient
implementation of HMC for researchers in the broader community to use.
Between 2012 and 2014, HMC saw empirical success in academic and industrial applications [13, 21]. At this time, the reason for HMC’s success and efficiency was poorly understood
until 2014 when Betancourt et al. [13] provided a rigorous grounding of the algorithm in differential geometry. Three years later, Betancourt published a companion article [11] providing
a conceptual introduction to the algorithm, making the findings of his differential geometry
research more accessible. An important finding from this research is that HMC focuses its
computational resources on exploring the typical set of the posterior distribution, a region of
the parameter space where the product of probability density and volume are largest [11]. Contributions to computations of expectations (often expressed as an integral of the product of
probability density and infinitesimal volume) come primarily from the typical set, explaining
why HMC is so efficient and successful; HMC focuses on exploring the regions of parameter
space which matter most [11]. Insight into the geometric theory of HMC also explains how
MAP may not be suitable as a means of summarizing the posterior for all models (especially
models with many parameters). MAP seeks the mode of the posterior distribution, (i.e. the
region where posterior probability density is largest). The intuition underlying MAP is that
integration is a linear operation, and so since expectations are integrals involving probability
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density, then the integral and hence the expectation are primarily influenced in regions where
probability density is largest [11]. However, there exists more volume away from mode in high
dimensional space than in a neighbourhood around it. Consequently, regions of high density
do not contribute as much to computations of expectations because the volume in these regions
is too small [11]. In summary, regions around the mode contribute negligibly to expectations
and methods which prioritize the mode can fail to capture the posterior with sufficient fidelity.
Despite these findings, MAP has remained a popular method for performing Bayesian inference, and has seen continued use in the pharmacokinetic and personalized medicine literature
as recently as 2022 [40]. Brooks and colleagues published a review article in 2016 on the use of
Bayesian estimation for tacrolimus exposure [16]. They identified 14 studies which used MAP
to estimate the AUC as an indicator of tacrolimus exposure [16]. Sturkenboom used MAP to
derive a limited sample strategy for rifampicin, an anti-tuberculosis drug, in 2015 [104, 105].
Kruizinga et al. used MAP to fit a population pharmacokinetic model of clonazepam from
saliva and plasma samples [57]. Lastly, Gibert et al. used MAP to model apixaban concentrations, providing an online tool for estimating patient decay times [40].
Population pharmacokinetic models like the ones used in the aforementioned studies can
contain 3 parameters or more (typically clearance, elimination rate, and absorption rate, depending on the model used) and can often contain random effects for each patient for each
parameter. Assuming N patients are used, the dimensionality of the model used scales like 3N.
In the aforementioned studies, the number of patients ranges from 9 [40] to 55 [105], meaning
the resulting parameter space has upwards of 150 dimensions. At this dimensionality, differences between MAP and HMC become salient. While MAP can be a good approximation to
the posterior distribution for some models, it remains to be seen to what extent MAP offers
an appropriate approximation to the posterior of population pharmacokinetic models, in both
a predictive and decision making context. If a Laplace approximation is made, the resulting
estimates of parameter uncertainty may differ between MAP and HMC due to the assumption
of constant curvature in the log posterior. Because decision making in a Bayesian framework
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integrates over uncertainty, this has the potential to appreciably effect the decisions made from
Bayesian pharmacokinetic models in personalized medicine.

3.2

Dynamic Treatment Regimes for Decisions Motivated by
Pharmacokinetics

Much of the recent work on DTRs focuses on estimation of the value function and use of Qlearning or similar techniques for estimation of the optimal policy. Chen et al. [26] extended an
application of O-learning from Zhao et al. [125] to the case with continuous treatment values
(i.e. doses), applying their technique to Warfarin (an anti-thrombotic drug similar to apixaban).
Laber and Zhao [58] proposed an approach to estimating optimal personalized treatment rules
using decision trees, placing emphasis on their interpretability. They applied their approach to
data on a major depressive disorder to illustrate its effectiveness. Li et al. [60] estimate individualized dose rules by directly balancing risks of toxicity and outcomes using a large number
of biomarkers and patient covariates and an ℓ1 penalty. They applied their method to patients
on radiation chemotherapy for lung cancer. Park et al. [80] demonstrate a semi-parametric approach to estimating the dose by covariate interaction effects on treatment response and demonstrate this approach on Warfarin dose outcomes with clinical and pharmacogenetic data. Rich
et al. [86] design a sequential multiple assignment randomized trial for optimal dose selection,
and demonstrate their design by simulating data from a pharmacokinetic model based on Warfarin. They contrast Q-learning and G-estimation for estimating the parameters of various value
functions which incorporate various different sources of information into the individualization
process.
Though the aforementioned studies focus on sequential decisions for drug dosing, they do
not explicity use drug concentrations as their outcomes. In particular, the studies concerning
applications to Warfarin focus on the International Normalized Ratio (INR), a measure of blood
thinness, as an the outcome. Warfarin is known to have narrow therapeutic window [68] as
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well as drug and food interaction [54]. Determination of a maintenance dose is consequently
a procedure with frequent monitoring and followup [22], with some sources recommending
monitoring for up to 12 weeks with stable INR [49]. The narrow therapeutic window forces
investigators to also consider the pharmacodynamics of Warfarin in addition to the pharmacokinetics when determining dose size as concentration of the drug alone is not sufficient to
infer the antithrombotic effect in patients. The relationship between dose, concentrations, and
pharaconyamic effect can be difficult to expressly relate, thus prompting researchers to estimate the value function (based on INR) using sufficently flexible regression method. However,
because the value function must be estimated, there is a risk of model misspecification.

The introduction of factor Xa (read as “factor ten A”) inhibitors, like apixaban, has alleviated some of the difficulties in prescribing anticoagulants. Factor Xa inhibitors have been
shown to have lower risk for bleeding than Warfarin in patients with atrial fibrillation [110]
and that the plasma concentration of the drug closely correlates with its thinning effect [18],
making pharmacokinetic modelling more informative on anti-thrombotic effect as compared to
Warfarin. However, a 2019 study at Western [106] discovered that there was more variation in
apixaban concentrations than what had been reported in clinical trials. These findings raised
questions as to the optimal dosing of apixaban for patients in different settings.

Because apixaban concentrations correlate closely with anti-thrombotic effect, there is an
opportunity to use concentration in computation of the reward for a DTR. This would alleviate
the need to estimate the reward function, thereby alleviating concerns of model misspecification. The attention would then turn to the model for estimating concentrations, which could be
supported by domain expertise from clinical pharmacologists.
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3.3

Combining Pharmacokinetic Data and Pooling
Information

Personalized medicine seeks to understand and explain heterogeneity in response and safety
to drugs. Hence, there may be the need to tailor models for a specific population. To that
effect, research on how clinical and genetic factors affect drug concentrations and adverse
events is increasingly happening in academic medical centres [41, 43, 81, 44, 103]. Many of
these studies use proprietary software like NONMEM [6] to fit their models, closely emulating
research into pharmacokinetics done by drug companies [27, 113].
Those studies which do not use NONMEM or similar software may resort to linear models [45]. Though linear models are a strong and popular tool for applied statistical modelling,
they suffer from multiple drawbacks for pharmacokinetic research, including misspecification
of the pharmacokientic function, under determination of the effects of covariates, and inability to incorporate uncertainty from one pharmacokientic parameter into another (for example,
uncertainty in the time to max concentration into estimates of the max concentration). Additionally, the studies into pharmacokinetic modelling often use variable selection methods
(including fitting all submodels [27, 113]). There are known deficiencies to variable selection
approaches including but not limited to: bias away from the null [121], exaggerated precision
[4], inaccurate or uninterpretable p−values due to inability to properly incorporate uncertainty
in the selection process [46], and failure to select the “true” model with high confidence even
when modelling assumptions are consistent with the true data generating process [98]. Variable selection is intended to answer “which variables are important to modelling the outcome”,
and as a consequence those variables which are not selected are considered as “negligible.”
In the Bayesian setting, different methods are used for this purpose. In particular, Bayesian
models with sparsity inducing priors have been used as a means of selecting relevant predictors of clinical outcomes, especially in the genome wide association literature [76, 5, 126].
In these approaches, effects are regularized towards a null effect, with a few variables having
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appreciable impact and the remaining having negligible impact. The resulting estimates are
biased towards the null, but in taking on this additional bias the resulting estimates have lower
variance. For some studies, especially exploratory studies where the goal is to discover new
avenues for future research, this trade off may be acceptable.
Additionally, academic medical centres may not have access to the same resources a drug
company would, limiting their ability to run clinical studies with tightly controlled conditions.
Consequently, drug concentration data can come from both tightly controlled studies [109] and
observational studies such as those from a personalized medicine clinic [106, 45]. The tightly
controlled studies often can sample subjects multiple times from a single dose (as well as on
an empty stomach, eliminating any possible effects of diet) facilitating estimation of between
subject variation, while the observational studies often collect a single sample from patients.
Combining these two types of data would be the most efficient use for academic researchers,
and existing research [27] has combined these types of data for estimation of pharmacokientic
parameters. Because data coming from observational studies only have a single observation,
estimation of between subject variation is precluded, meaning between subject variation manifests as increased residual variance. This difference in residual variance between observational
and controlled clinical studies means patients can not be treated as exchangeable. Exchangeability is closely related to the IID assumption, and treating data as exchangeable when they are
not is similar to treating data as IID when they are not. The result is exaggerated precision in
resulting estimates and possible attenuation/exaggeration of effects. Since these estimates are
used to make decisions, extreme outcomes are less probable due to the exaggerated precision
and extreme outcomes are hence estimated to be less likely than they are in reality.
The increase in pharmacokinetic research at academic centres for personalized medicine
stands to benefit from models which can properly pool information between studies, avoid
problems associated with variable selection, and are written in open source languages.

Chapter 4
Comparisons Between Hamiltonian
Monte Carlo and Maximum A Posteriori
For A Bayesian Model For Apixaban
Induction Dose and Dose Personalization
This chapter represents joint work with Dr. Dan Lizotte presented at Machine Learning for
Healthcare 2020. I conceived of the approach, researched the model priors, implemented the
model and performed the experiments. Dr. Lizotte participated in conception and planning,
and interpretation of research as well as critical review of the drafted materials.
The motivation for the work came from researching the implementation of Hamiltonian
Monte Carlo as well as researching Bayesian approaches in pharmacokinetics. Many pharmacokinetic studies which used Bayesian techniques also used Maximum A Posteriori to fit their
models. My research into Hamiltonian Monte Carlo signalled a possible detriment to use of
Maximum A Posteriori, and so I decided to implement a toy pharmacokinetic model using both
to see for myself.
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Introduction

Personalized medicine’s slogan is “right drug – right patient – right time”. Implicit in the slogan
is “right dose”; however, determining the right dose for any one patient can be challenging. The
anticoagulant Warfarin offers a good example of these challenges; physicians choose an initial
dose based on guidelines and their own experience. They then closely monitor the patient’s
International Normalised Ratio (INR), which measures how long it takes blood to clot, and in
response they adjust the dose over time.
Pharmacokinetic and statistical models of how drugs behave within an individual can alleviate some of these challenges by predicting the effects of different doses based on patient
covariates. In some studies [96, 99, 20] a cohort of patients will have an appropriate maintenance doses determined empirically and these are then regressed onto patient covariates. In
others [77, 127, 123] patient pharmacokinetics are directly modeled and can be simulated under different dosing regimens to find an appropriate dose. In both cases, uncertainty in the
models can be assessed and can help guide clinical decisions as to what dose is best or what
dose to try next.
Both types of models can provide guidance for individual patients, but only when there is
enough data so that the models are accurate and reliable. For personalized pharmacokineticsbased dosing, this amount of data is rarely available in practice. Obtaining sufficient data to
learn a patient’s pharmacokinetic parameters requires a lengthy observation period which few
patients are willing or capable of committing to. Population pharmacokinetic models could be
used in place of a patient’s pharmacokinetics, but treating the patient as “average” is precisely
what personalized medicine seeks to improve upon.
In many contexts where limited data area available, Bayesian methods with informative
priors have been proposed. Model priors allow analysts to specify their beliefs about model
parameters prior to seeing a new patient’s data, and to combine those beliefs with new observations to form personalized predictive models. This allows models to “hit the ground
running” so to speak, and makes use of all available data to support decision-making. To use
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all but the simplest of Bayesian models for decision-making requires computational approximation techniques to obtain model estimates and predictions. Several approaches exist for
generating approximate samples from the posterior distribution, with Hamiltonian Monte Carlo
(HMC) being considered the gold standard [74, 47, 21, 111]. Despite HMC being the preferred
method by theorists and applied Bayesians alike, methods like Maximum A Posteriori (MAP),
in which the posterior mode is computed via optimization and then a Laplace approximation
is performed, continue to be used in population Bayesian pharmacokinetic studies as late as
2020 [16, 75, 84, 102]. HMC and MAP are two different approaches with different strengths
and different theoretical motivations. Naturally, this raises questions regarding how decisions
in personalized medicine may be affected by the use of different methods for performing inference, even using the same model and data. We seek to answer these questions by developing
a new, high-fidelity Bayesian pharmacokinetic model and then investigating the impact of the
choice of inference method on personalized medicine decisions.

Generalizable Insights about Machine Learning in the Context of Healthcare
The main methodological insight we gained was that although predictions made by HMC and
MAP may appear to be very similar according to common error metrics, they can lead to very
different personalized dosing decisions. The main contributions of this paper are as follows:
1. A new Bayesian model for apixaban pharmacokinetics written in an open source Bayesian
language. We make the model code and posterior summaries of all parameters publicly
available at https://github.com/Dpananos/PKBayes.
2. A simulation study demonstrating that inferences made via MAP and HMC lead to very
different dosing strategies.
3. An induction dosing model for apixaban based on desired trough concentration level
after a first dose.

4.2. Background
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Background

Pharmacokinetic Modelling
Pharmacokinetics is the study of the dynamics of a mass of drug in the body and is concerned
with the absorption, distribution, metabolism, and elimination of that drug. Differential equations (equations which relate the derivative of an unknown function to itself) are often used to
describe how these dynamics evolve over time. The differential equation models in pharmacokinetics are called “compartmental models” as they idealize different parts of the body as
compartments among which the drug can flow in and out at rates proportional to how much
drug is presently in that compartment. If the differential equation is not too complex, the solution can be written in terms of analytic functions. In the case where the differential equation
cannot be solved in terms of analytic functions, a rich literature of numerical techniques exist to
approximate the solution to within quantifiable precision. In either case, estimation of model
parameters is of interest as they represent pharmacokinetic measures, such as the volume of
distribution or rate constants for which the drug is absorbed into/excreted out of a compartment. If the parameters for such a model are known, we can use the model to make predictions
about drug concentration as a function of time and dose. This in turn can be used to select a
dose that meets given criteria about what the concentration function should look like.
Parameter estimation for these models can be done in both frequentist and Bayesian frameworks. In a Bayesian framework, parameter estimation begins by specifying a prior distribution
which reflects the knowledge of parameters before seeing data. Once data are observed, Bayes’
rule can be used to get the posterior distribution. This distribution provides information about
what parameter values have most plausibly generated the observed data. By virtue of being
a probability distribution, the posterior can be summarized by expectations to get point estimates of model parameters. Shown in figure 4.1 is a visual summary of how Bayes’ rule and
Bayesian modelling of pharmacokinetics works using pseudodata. The leftmost panel is our
prior distribution. Each concentration curve results from specific combinations of parameters
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for the model which are believed to be plausible before seeing data. Once data are observed
(the middle panel), application of Bayes’ rule yields the rightmost panel. Concentration curves
in this panel correspond to combinations of parameters which have most plausibly generated
the data, resulting in concentration curves which have most plausibly generated the data. Note
that in this setting, because we have many measurements, the pharmacokinetic model is welldetermined and the posterior uncertainty is small. Except in very simple cases, the integrals
required to evaluate the posterior become intractable; thus, computational approximations are
required to fit Bayesian models.

Figure 4.1: A demonstration of a Bayesian workflow for pharmacokinetic models. The leftmost
panel represents the prior. Each curve corresponds to a unique set of model parameters which
induce each concentration function. In the center panel is the data observed from a single
patient. Conditioning on this data yields the rightmost panel. Each curve corresponds to a
unique set of model parameters drawn from the posterior distribution.

Dosing Decisions
Vitamin K antagonists, such as the popular oral anticoagulant Warfarin, are known to have narrow therapeutic windows as well as drug and food interaction. Determination of a maintenance
dose is consequently a procedure with frequent monitoring and followup, with some sources
recommending monitoring daily or every other day until the INR stabilizes for two days. The
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narrow therapeutic window forces investigators to also consider the pharmacodynamics (the
study of the onset, intensity, and duration of the drug response and how these are related to
the concentration of the drug at its site of action) of Warfarin in addition to the pharmacokinetics when determining dose size as concentration of the drug alone is not sufficient to infer
the antithrombotic effect in patients. The introduction of factor Xa inhibitors like apixaban has
alleviated some of the difficulties in prescribing anticoagulants. Factor Xa inhibitors have been
shown to have lower risk for bleeding than Warfarin in patients with atrial fibrillation [117] and
also allow for fixed dosing without frequent monitoring of INR. Furthermore, unlike Warfarin,
the pharmacodynamic effect of apixaban on clotting is closely correlated with the concentration
in the plasma [18], making pharmacokinetic modelling more informative on antithrombotic effect as compared to Warfarin. However, as of writing this paper there is little information on the
therapeutic window, making selecting dose sizes large enough to avoid thromboembolism difficult. Furthermore, studies have demonstrated that inter-patient variability of apixaban plasma
concentrations is much higher than was initially believed [45]. In this work, we develop personalized dosing whose goal is to find the dose that avoids plasma concentrations that are too
low or too high.

4.3

Methods

Bayesian Model
To achieve our three objectives of 1) developing a new Bayesian pharmacokinetic model for
apixaban, 2) investigating the impact of MAP versus HMC inference on dosing decisions and
3) developing an induction dosing model for apixaban, we fit a hierarchical mixed effects model
of apixaban pharmacokinetics using data from [8]. Thirty-six participants were given 2.5 mg
of apixaban and 100 ml of water in a fasted state. Blood plasma concentrations of apixaban
were recorded over the course of 12 hours.
Since participants were given a single dose of apixaban in a fasted state, we use a single-
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Table 4.1: Summary of data from [8] to fit our hierarchical pharmacokinetic model. Each of
the 36 patients was observed 8 times over the course of 12 hours.

compartment pharmacokinetic model with first order absorption and elimination. The model
can be written as a differential equation, namely

dC FDka ke
=
exp(−ka t) − keC(t) , C(0) = 0 .
dt
Cl

(4.1)

Here, D is the size of the dose in mg, F is the bioavailability (fixed to 0.5 for apixaban [18]), Cl
is the clearance rate in units litres per hour, ka is the rate constant of absorption into the volume
of distribution in units 1/hours, and ke is the elimination rate constant in units 1/hours. The
differential equation can be non-dimensionalized by letting τ and y(τ) be the non-dimensional
quantities, and letting C(t) = ke ka FDy(τ)/Cl and t = τ/ka . The non-dimensionalized differential equation is then

dy(τ)
= exp(−τ) − αy(τ) .
dτ

(4.2)

Here, α = ke /ka is the ratio of elimination and absorption rates, and is dimensionless. The
differential equation’s qualitative behaviour depends solely on this ratio, with all parameterizations in which α is constant displaying the same qualitative behaviour. The remaining variables
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Cl, D, and F only serve to scale the solution vertically. The solution to this differential equation
(obtained via integrating factors or the Laplace Transform) is

y(τ) =


1 
exp(−τ) − exp(−ατ)
α−1

(4.3)

After solving the differential equation and converting back to dimensional variables, the solution to the differential equation describing mass transit, and consequently the concentration
function, is then

C(t) =


FD ke ka  −ka t
e − e−ke t .
Cl ke − ka

(4.4)

Figure 4.2: Non-dimensionalized concentration plotted against non-dimensionalized time. The
process non-dimensionalizing the differential equation removes all units from the model, allowing for qualitative comparisons of the solution under different families of parameterization.
Here, it is shown that all parametrizations in which α = ke /ka = 0.15 elicit larger concentrations than those parameterizations in which α = 0.4 conditioned on FD/V remaining constant.

For our model, we use a slightly modified version of this function
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!


F · D ke · ka −ka (t−δ)

−ke (t−δ)


e
−e
δ≤t



Cl ke − ka





C(t) = 











else
0

(4.5)

We include a time delay, δ, to relax the assumption that absorption begins immediately after
ingestion. Parameters are modelled using random effects, with some population mean and
variance (which is estimated from the data).
Priors for ke and ka are not defined explicitly. Rather, our model puts priors on the time
to maximum concentration, which can be expressed as a function of the parameters in equation (4.5)

tmax =

ln(ka ) − ln(ke )
ka − ke

(4.6)

and on the ratio between ke and ka , which we call α

α=

ke
.
ka

(4.7)

We choose to place a prior on the quantity α because it arises when non-dimensionalizing [50]
the differential equation governing mass transit of the drug in and out of the volume of distribution. The plasma concentration function is a version of the “flip-flop” model [120, 92],
since different parameterizations of this model can yield the same curve, leading to model unidentifiability. To ensure the model is identifiable, we require ke < ka as has been done in
previous Bayesian analyses of this model [120, 92]. This requirement bounds α to the unit
interval. Using a standard parameterization of the model (in terms of ke and ka ) resulted in
poor sampling behaviour as indicated by the sampling diagnostics. In particular, because of an
unenforceable constraint that ke < ka or ka < ke , the model suffered from poor mixing as indicated by the Gelman-Rubin diagnostic R̂. Wakefield approached the problem of identifiability
by [119] by placing priors on ka , and V (the volume of distribution for the drug) and Cl for
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patients separately, (thereby allowing him to solve for ke ), however there was insufficient prior
information on ka and V for apixaban. Placing a relatively non-informative prior determined
through prior predictive checks on α and using the estimate of time to maximum concentration
(tmax , for which there was prior information) allowed us to solve for either ke or ka and then use
the relationship α = ke /ka to solve for the remaining rate constant. This rectified the poor mixing behaviour and facilitated sampling with HMC. In principle, information on the elimination
rate constant could be obtained by performing a linear regression on the log concentration values in the latter half of the concentration profiles where the drug is being eliminated from the
body. To preserve as much data as possible for model fitting, we forgo this approach. These
two sets of equations are used to parameterize the absorption and elimination rate constants as
follows
ka =

1 ln(α)
tmax α − 1

ke = ka α

(4.8)
(4.9)

Details on the prior distributions for each parameter and the model likelihood can be found
in the appendix. We also include a summary of the model’s posterior as well as details on
simulating data from the model’s posterior predictive distribution to generate pseudopatients
for use in our experiments.

Model Fitting and Diagnostics
For HMC, prior/posterior predictive checks and model fitting was performed using Stan [21]
to draw from the prior/posterior. Twelve chains were initialized and run for 4000 iterations
each (1000 for warmup allowing the Markov chain the opportunity to find the correct target
distribution and 3000 to use as samples from the posterior). Stan monitors several diagnostics
none of which detected problematic HMC behavior1 .
1

0 divergences, all Gelman-Rubin diagnostics < 1.01, smallest effective sample size ratio 16%.
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We use Stan’s optimization capabilities to compute the MAP estimates. The L-BFGS op-

timizer was used to find the posterior mode. The optimizer terminated when either 10,000
iterations had been performed or when the value of the objective function stopped changing
within a tolerance of 1 × 10−10 . Once the mode was located, 10,000 samples from the Laplace
approximation to the posterior were obtained. Constrained parameters were transformed to the
appropriate space before sampling.

Determination of a Personalized Dose
The results from both HMC and MAP yield samples from the approximate posterior of Cl j , ke, j ,
ka, j , and δ j for each of the j patients. For any given posterior sample, these parameters can be
combined to compute a predicted concentration for patient j at time t by using equation (4.5).
We determine a personalized dose size by evaluating the pseudopatients’ concentration function under different dose sizes D and then computing posterior probabilities of failing to surpass
concentration thresholds. When we have posterior samples, equation (4.5) turns into a function
of the dose size and time conditioned on patient.
We perform two experiments to compare HMC and MAP. In our first experiment, we determine the posterior probability of failing to exceed a concentration of 20 ng/ml 12 hours
post dose for each pseudopatient across a variety of dose sizes. We choose 20 ng/ml as our
threshold for this experiment because the median concentration at 12 hours post dose in the
data from [8] is approximately 20 ng/ml. In our second experiment, we determine the posterior
probability that the maximum concentration fails to exceed 80 ng/ml. We choose 80 ng/ml as
our threshold for this experiment because the median maximum concentration in the data is
79 ng/ml (though it is important to note that it is unlikely that these patients were observed
exactly at the time which the peak concentration was achieved). These quantities represent
two different ways of assessing a patient’s risk of being below a given threshold. The chosen
threshold is arbitrary, but our method generalizes to any threshold. For each experiment, the
risks are computed across a grid of dose sizes of 0 mg to 60 mg, yielding risk as a function of
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dose size. For each pseudopatient, we interpolate these estimates using a monotone Hermite
spline and then invert the risk curve; the inverted risk curve maps risk to dose. This allows us
to determine a dose size which produces a specified risk level.

4.4

Results

Bayesian Model
Diagnostic plots for our Bayesian model fit to the real apixaban data are shown in figure 4.3.
Posterior population prediction intervals (that is, the result of integrating out the random effect
of each patient) of the observed concentration are realistic and to the eye appear similar to the
observed data (top left of figure 4.3). Residual plots (observed minus posterior mean) indicate
homogeneity of variance on the log scale, which is consistent both with expert knowledge on
the measurement process and the likelihood we choose (bottom left of figure 4.3). Predicted
concentrations tend to agree with observed concentrations (top right of figure 4.3), and posterior predictive draws have similar empirical cumulative distribution functions as the observed
data (bottom right of figure 4.3 ). In figure 4.4, we show concentration functions obtained from
draws from our prior distribution as well as two patients with best and worst fit as measured by
mean absolute percentage error (best: 3.29%, worst: 26.4%). Because our HMC diagnostics
do not indicate problematic behaviour in the Markov chains, and because the model diagnostics indicate adequate fit, we believe the obtained model’s posterior predictive distribution is
adequate for simulation of pseudopatients.

Fit on Simulated Patients Using HMC and MAP
Initial comparisons of predicted values indicate that both HMC and MAP yield similar predictions to one another, and similar predictions to actual values of unseen data. Examining
predictions alone, it would seem that HMC and MAP are equivalent, or at the very least sim-
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Figure 4.3: Diagnostic plots for our Bayesian model fit to the real data. Top left shows the posterior predictive distribution plus observed data. Data points gave been perturbed to prevent
overlapping. Top right shows the predicted values along with accompanying 95% equal-tailed
posterior credible interval. Bottom left shows the residuals (on the log scale) between the observed concentrations and the posterior mean concentration, bottom right shows the cumulative
density function for the observed data (black) as well as draws from the posterior predictive
distribution (gray).
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Figure 4.4: The leftmost panel shows 250 draws from the prior defined in the previous section.
The center panel shows data from two patients who achieved the best (blue) and worst (red)
model fit as measured through mean absolute percent error. The rightmost panel shows 250
draws from the posterior for these patients. Not shown here are the other 34 patients in our
data, for which the model is also capable of performing predictions for.

MSE (SD)
MAE (SD)
MAPE (SD)

HMC
6.67 (15.93)
1.71 (1.94)
0.04 (0.03)

MAP
8.57 (19.93)
1.97 (2.17)
0.05 (0.03)

Table 4.2: Comparison of HMC and MAP on three loss functions common in pharmacokinetics: Mean Squared Error (MSE), Mean Absolute Error (MAE), and Mean Absolute Percentage
Error (MAPE). The loss was computed on samples not seen by our model. Included in parentheses are the standard deviations of the loss values.
ilar enough so as to not have strong preference for one over the other. When using posterior
means, HMC results in lower prediction error on unseen data (see table 4.2) as measured with
Mean Squared Error (MSE), Mean Absolute Error (MAE), and Mean Absolute Percentage Error (MAPE), but these are not stark differences. Estimates of posterior uncertainty between
MAP and HMC can however vary a great deal. Shown in figure 4.5 are 19 of the 100 simulated patients which have a MAP equal tailed posterior interval at least 50% larger as compared
to their HMC equal tail posterior interval at the widest point. We note that while not shown
explicitly, unobserved concentrations lie entirely within the HMC and MAP posterior intervals.
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Figure 4.5: Comparisons of equal tail posterior intervals from MAP and HMC. Note that the concentration scales differ from subplot to
subplot. Selected patients are those which have a MAP posterior interval at least 50% as wide or wider than their HMC interval.
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Difference in Estimated Dose To Achieve Target Risk
Using the posterior for each pseudopatient, we can determine the risk of exceeding the threshold by varying the dose. This results in a risk curve which gives risk as a function of dose.
By inverting the risk curve, we can obtain dose size as a function of risk. Shown in figure 4.6
are the differences between doses computed from HMC and MAP posteriors to achieve the
indicated level of risk. The left panel shows the difference in doses in order to achieve a concentration of at least 20 ng/ml 12 hours post dose. For a majority of patients, MAP and HMC
agree to within 1 mg though some pseudopatients see a much larger dose recommendation by
HMC than by MAP. The right panel shows the difference in doses in order to achieve a maximum concentration of 80 ng/ml. MAP tends to always recommend larger doses than HMC for
this scenario, with the difference between recommended doses becoming larger as the desired
risk becomes smaller.

Figure 4.6: Left: Differences between the estimated doses from MAP and HMC to achieve
the indicated risk of having a concentration of apixiban smaller than 20 ng/ml at 12 hours post
dose. Each line corresponds to one of the 100 pseudopatients. HMC tends to recommend
larger doses than MAP to achieve a desired risk of having the patient’s concentration at 12
hours post dose be below 20 ng/ml. This tendency to recommend larger doses is consistent
across desired risk levels. Right: Differences between estimated doses from MAP and HMC
to achieve the indicated risk of having a maximum concentration smaller than 80 ng/ml. Some
pseudopatients see dose recommendation differences as large as 10 mg and are thus cut off by
the vertical axis limits. Red lines indicate where the two methods would perfectly agree.
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Calibration for Dosing Decisions
Since all pseudopatients were simulated, the true concentration function as a function of the
dose size (equation (4.5)) was known. To further compare HMC and MAP for decision making,
we took estimated dose size to achieve a desired risk and computed what the concentration
curve under the recommended dose size. We could then compute the number of pseudopatients
which actually exceeded the threshold, thus allowing us to examine the calibration of HMC and
MAP. The calibration curves for HMC and MAP for both experiments are shown in figure 4.7.
In the first experiment (left of figure 4.7), HMC is better calibrated than MAP. This means
that when a dose is selected, in order to a achieve a risk of being below 20 ng/ml at 12 hours
post dose of r, approximately r × 100 pseudopatients have a true concentration function which
is smaller than 20 ng/ml at 12 hours post dose. In contrast, MAP is poorly calibrated, and sees
more pseudopatients failing to exceed the 20 ng/ml threshold than was desired. Calibration in
our second experiment again shows than HMC is better calibrated than MAP, but calibration
seems to become worse as the desired risk becomes larger. When we use dose sizes recommended by MAP to achieve a 50% probability of exceeding the 80 ng/ml threshold, only 26%
of pseudopatients actually have a maximum concentration which exceeds the threshold.

4.5

Discussion

While prediction errors of the point estimates produced by MAP and HMC are very similar
as measured by three losses common to pharmacokinetic research, they each produce very
different estimates of uncertainty. Such estimates are necessary for decision making under uncertainty, where an expected loss is computed over a posterior distribution. In this study, for
a given dose, MAP assigns a significant amount of probability mass to concentrations which
are far lower than the concentrations considered plausible by HMC. The extent to which this
discrepancy would change decisions depends on the loss function, but we see substantial differences in our two example experiments for personalized dosing. The difference in uncertainty
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Figure 4.7: Left: Calibration curves for assessing risk of being below 20 ng/ml. Each dot
represents the proportion of the 100 pseudopatients which fail to exceed the 20 ng/ml threshold.
When doses are chosen from samples obtained via HMC, then probabilities are well calibrated.
When doses are chosen from samples obtained via MAP, more pseudopatients fail to exceed
the threshold than were specified. Right: Calibration curves for assessing risk of the maximum
concentration being below 80 ng/ml. HMC appears to be better calibrated than MAP, though
the calibration could stand to improve.

between MAP and HMC results in small disagreement for dose size for the majority of patients,
but very large disagreement for a sizable portion. The observed difference in uncertainty for
the concentration function between MAP and HMC are likely due to discrepancies in uncertainty over the individual PK parameters: Each of the 19 pseudopatients in figure 4.5 see MAP
and HMC disagree strongly on posterior uncertainty for the parameters ka and ka . MAP lends
credence to higher values of ka and lower values of ke as compared to HMC. The differences
in uncertainty in these parameters is likely the cause of the observed difference in uncertainty
in concentration levels. This translates into much wider equal-tailed posterior intervals for
concentration using MAP, with 19 out of 100 patients having an MAP equal tailed posterior
credible interval at least 50% as wide or wider at their widest point than their HMC equal tailed

52

Chapter 4. Comparisons Between HMC and MAP for Dose Personalization

posterior interval. For each of these 19 patients, MAP appears to have a lower interval estimate
far below that of HMC, making it appear as if lower predicted concentrations are probable.
This in can make a given proposed dose appear risky in terms of allowing concentration to fall
too low; which in turn leads to an increase in recommended dose when the model is asked for
a dose that bounds this risk.
While the posterior distribution for this model is too complex to be analyzed analytically,
there are good theoretical reasons to prefer HMC over MAP when analysts seek the posterior
expectation of some function of parameters. These reasons are nicely summarized by [11],
but can be explained by the fact that expectations are computed over volumes, and in high
dimensional space there exists more volume away from the mode than in a neighbourhood
around it. Because the volume near the mode is so small, these regions of parameter space
contribute negligibly to expectations. Instead, regions of parameter space where the product
of probability density and volume is large (i.e. the typical set) should contribute more to
expectations, and this is where our chosen method should be focusing its computational power.
Hamiltonian Monte Carlo does exactly this, and thus we prefer it to Maximum A Posteriori.
Neither HMC nor MAP provide perfect representations of the posterior, and discrepancies
between the two methods are expected. However, the degree of discrepancy observed in this
study and its impact on dosing decisions reveals that these techniques are not interchangeable.
One reason for the observed difference might be an insufficient number of observations. However, with 24 equally-spaced observations per each of the 100 simulated patients, this simulation study represents an extremely optimistic (and likely unrealistic) best case scenario. Even
specialized studies of pharmacokinetics would collect fewer samples from fewer patients, and
even less data collection is practical in clinical practice. Hence, even if MAP and HMC were
to converge to each other with enough data, this amount of data is not available in practice.
Another possible reason could be the chosen priors and/or the likelihood, but the model used
was identical for both inference methods and had strong priors informed by existing pharmacokinetic data. We note that our proposed model does not account for patient covariates (e.g.
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weight, BMI, creatinine, etc). Our model could be extended to include covariates as input to
the model to further personalize dose. Although our models did not account for patient covariates, a secondary analysis was performed in which patient level pharmacokinetic parameters
were regressed onto patient covariates. In this analysis, we observed the same disagreement
in model uncertainty as shown in figure 4.5. Because the uncertainty directly affects dosing
decisions, we believe a model sampled using MAP which included covariates would also show
similar calibration relative to a model sampled using HMC.

4.6

Conclusion

We have presented a new Bayesian model for apixaban pharmacokinetics and an induction
dosing model for apixaban based on desired trough concentration level after a first dose. We
have also presented a simulation study demonstrating that inferences made via MAP and HMC
lead to very different dosing strategies; from this simulation study, we derive some general
conclusions and guidelines for Bayesian pharmacokinetic modelling as applied to precision
medicine.
Bayesian modelling using informative priors provides a practical approach for developing
personalized dosing strategies when data are limited. However, the evaluation of Bayesian
models, particularly with informative priors, typically focuses on the model itself - are the priors plausible? Do posterior predictive checks look appropriate? In this work, we have demonstrated that the inference technique can have an impact on decision making that is as important
as model fidelity, even when the impact on point prediction quality is minimal. Specifically,
we have shown that MAP-based inference, which is very commonly used in pharmacokinetics,
can lead to very different personalized dosing decisions than HMC-based inference, even in a
well-validated model.
Studies using MAP for Bayesian inference in pharmacokinetic models have been published
as recently as 2020. The speed and similarity to maximum likelihood makes MAP an attractive
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and familiar approach as compared to HMC, which can take several minutes to return samples and can use quite complex mechanisms to draw from the posterior. The aforementioned
studies have largely focused on point predictions of latent concentrations where, as we have
shown, MAP and HMC yield similar results. However, when uncertainty information is used
for decision-making, MAP and HMC can lead to very different outcomes.
We recommend that if practitioners do use MAP, that they also compare model results with
HMC. Libraries exist to perform HMC in a variety of languages including R, python, and Julia,
making HMC widely accessible. Use of these libraries has the added benefit of making analysis
more transparent and reproducible for the community at large.

4.7
4.7.1

Appendix
Model Priors

Time to maximum concentration values for patient j are drawn from a log normal distribution

tmax, j |µt , σt ∼ LogNormal(µt , σt )

(4.10)

and α is drawn from a weakly informative beta prior to prevent degenerate cases when α is 0
or 1. When α is near 0 or 1, concentration profiles become very extreme (either resulting in
very fast elimination of apixaban or very slow elimination of apixaban). To honestly reflect the
uncertainty in the value of α while also discouraging very extreme concentration profiles from
our prior model, we model α as

α j ∼ Beta(2, 2) .

(4.11)

The rate constants for patient j, ke, j and ka, j , are determined from equations (4.8) and (4.9).
The clearance rate is modelled hierarchically
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Cl j |µCl , σCl ∼ LogNormal(µCl , σCl ) .

(4.12)

Each patient is observed to have a non-zero concentration at time 0.5, so the time delay for
each patient is no larger than 0.5 hours. We place a beta prior on the delay

δ j |ϕ, κ ∼ Beta(ϕ/κ, (1 − ϕ)/κ)

(4.13)

and multiply delta by 0.5 in our model to ensure the maximum delay is 0.5 hours. Here, ϕ is
the mean of this beta distribution and κ determines the precision of the distribution. Shown in
figure 4.8 is a Bayes net to exposit model structure at a high level.
ϕ

κ

σt

µt

σCl

δ

α

tmax

Cl

t

y

µCl

σy

i = 1...8
j = 1 . . . 36

Figure 4.8: Graphical description of the data generating process for our model. The data
consist of 36 patients, indexed by j. Each of the j patients are observed a total of 8 times, with
each observation index by i. The data are generated by drawing random variables from their
appropriate distribution at the top level and then drawing child random variables directly there
after. As an example, ϕ and κ are drawn, which are then used to draw the δ j , which are then
used to draw each of the 8 concentration values, yi for each of the j patients.

Priors for Model Hyperparameters
Estimates of the time to maximum concentration for apixaban place the population median tmax
near 3.3 hours post dose [18]. Assuming the median and the mean are similar, this provides
information for µt and so we use specify
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p(µt ) = Normal(ln(3.3), 0.25)

(4.14)

The standard deviation of the prior for µt was selected via prior predictive checks in which
profiles are drawn and priors are assessed as realistic or not. Byon et. al [18] recreate a table
from [34] which lists the median, min, and maximum estimated time to max concentration for
apixaban. Hyperparameters for the prior on tmax were chosen so as to produce minimum and
maximum concentrations which were similar in prior predictive simulations. The population
variability of tmax was modelled as

p(σt ) = Gamma(10, 100)

(4.15)

again, using prior predictive checks to ensure that the resulting draws were comparable to those
listed in [18] and [34]. Using these priors, we recover similar median, min, and maximum tmax
values as reported by [18]. Similarly, we model the population mean and variability for the
clearance rate as

p(µCl ) = Normal(ln(3.3), 0.15)

(4.16)

p(σCl ) = Gamma(15, 100)

(4.17)

so that population estimates of the mean clearance rate are near 3.3 litres per hour with inflated
uncertainty to account for possible population differences. We use weakly informative priors
for ϕ and κ which induces an approximately uniform prior on δ.

p(ϕ) = Beta(20, 20)

(4.18)

p(κ) = Beta(20, 20)

(4.19)
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The tools used to measure the concentration of apixaban are believed to be within 10% of
the real concentration. This implies that the observational model is heteroskedastic. We use a
log-normal likelihood so that positivity of observed concentrations and heteroskedasticity are
respected. We place a lognormal prior on the likelihood’s variability with

p(σy ) = LogNormal(ln(0.1), 0.2)

(4.20)

y j (t)|Cl j , ka, j , ka, j , δ j ∼ LogNormal(ln(C(t)), σy )

(4.21)

Posterior Summarization and Generating New Data
Once our model was fit on the pharmacokinetic data, the marginal posteriors were summarized
to create priors for the new model. Parameters for these priors were determined by using
maximum likelihood on the posterior samples. The priors for the new model are as follows:

µCl ∼ Normal(1.64, 0.09)

(4.22)

σCl ∼ LogNormal(−0.94, 0.11)

(4.23)

µt ∼ Normal(0.97, 0.05)

(4.24)

σt ∼ LogNormal(−1.40, 0.12)

(4.25)

α j ∼ Beta(2, 2)

(4.26)

σy ∼ LogNormal(−1.76, 0.12)

(4.27)

Lognormal distributions were used to respect positivity of some parameters. The posterior
predictive distribution of the model fit to the data from [8] was then used to simulate 100
pseudopatients. The time delay, δ was not used to generate these data as δ does not affect
the overall shape of the concentration function, it merely shifts it right. The model with the
priors defined by equations (4.22) to (4.27) was then refit on the 100 pseudopatients in order
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to examine differences between HMC and MAP in a “best case” scenario. The pseudopatients
were sampled between 0.5 and 12.0 hours after ingestion in increments of 0.5. Draws from the
posterior were used to predict latent concentration for each patient at times 0.75 to 11.75 in
increments of 0.5.

Chapter 5
Developing and Evaulating
Pharmacokinetics-Driven Dynamic
Personalized Medicine: A Framework and
Case Study
This paper represents joint work with Drs. Rommel Tirona, Simon Bonner, and Dan Lizotte.
I am the primary author of this work and was responsible for implementation of the Bayesian
models, implementation of Q learning, as well as writing the manuscript. Dr. Lizotte participated in conception and planning, and interpretation of research as well as critical review of
the drafted materials. Dr. Tirona provided expertise on the pharmacokinetics of apixaban, and
Dr. Bonner provided statistical support on the models and ensured the sections were consistent
and accessible to the statistical readership.
This chapter was submitted to Medical Decision Making. The motivation for this paper
was initially only to demonstrate how to perform Q-learning to estimate an optimal dynamic
treatment regime with pharmacokinetic models. However, as the project proceeded, questions
as to what kind of personalization to study arose. Eventually, we opted to develop a framework
59
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to evaluating different kinds of personalization against the costs (monetary or otherwise).

5.1

Introduction

Personalized medicine has been characterized by four goals: 1) to identify drugs for which
between-subject variability in effectiveness or toxicity is a key issue for effective treatment,
2) to identify predictors which may explain this variability, 3) to decide on the right dose of
the right drug by considering these factors, and 4) to prevent adverse reactions to drugs [70].
Progress in all four goals has accelerated within the last decade: For example, recent studies on DPYD genotype testing prior to starting fluoropyrimidine-based chemotherapy showed
promise in preventing adverse events, making good arguments for integration of DPYD genotype testing into standard of care practices [122].
With regard to the third goal—personalized dosing—the intent of most efforts has been
what we call static personalization. Such approaches inform dose at one point in time (usually
induction) with the goal of eliminating the need for “trial-and-error” adjustments (titration)
where the dose is adapted to the patient over time in response to its effects, both therapeutic
and adverse [70]. Although significant progress has been made, for example in warfarin dosing
[42], the need for titration has been reduced but not eliminated. Thus, there is an opportunity to
personalize not only the initial doses but also the titration process to achieve the best result—we
call this dynamic personalization. This approach has been used in other contexts by applying
techniques from disciplines such as control theory, operations research, machine learning, and
biostatistics to define and apply models for optimal sequential decision-making for patient care
[124, 32].
Despite its potential to improve care, dynamic personalization imposes additional burden
on the patient and provider, because it requires ongoing monitoring, for example by gathering
lab results and returning for additional clinic visits. It is therefore natural to ask whether
dynamic personalization is “worth it.” Is the additional control over dose worth the additional
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burden? To help answer this question, we present a unified framework for the development and
simulation-based evaluation of static and dynamic personalization based on pharmacokientic
(PK) modelling. The knowledge created by our framework can be integrated into a systemlevel decision-making framework like Know4Go, for example, which can be used to evaluate
whether such a personalized medicine program should be implemented into a particular health
care system [65]. Having established our framework, we investigate the static and dynamic
personalization of apixaban dosing as a case study.
We begin in Section 5.2 with an overview of dynamic treatment regimes, which underpin
our models for dynamic personalization, and we review Bayesian PK modelling, which allow
us to predict drug concentrations and to generate simulated patient data. In Section 5.3, we
present our framework, which describes how to estimate optimal dynamic treatment regimes
for personalization by combining Bayesian PK modelling with Q-learning, and describe a
simulation-based approach for assessing the potential benefits of different modes of static and
dynamic personalization. We then present our case study of personalized apixaban dosing in
Section 5.4. Finally in Section 5.6 we discuss the results of the case study, and we identify
broader issues relevant to the further development and implementation of PK-driven static and
dynamic personalization.

5.2

Methods

We briefly review dynamic treatment regimes, which are used to develop optimal decisionmaking models, and Bayesian PK models, which are used to capture relationships among patient characteristics, measurements, pharmacokinetics, and dose so that optimal dosing decisions can be derived using the dynamic treatment regime framework.
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5.2.1

Dynamic Treatment Regimes

A dynamic treatment regime (DTR) is a mathematical formalism intended to model the practise
of evaluating a patient, choosing a treatment, and observing a response. A DTR is defined as a
sequence of decision rules d = (d1 , · · · , dK ), each of which is a function that takes information
about a patient produces an action, like a dose initiation or change, that is intended to affect
the status of the patient, like their plasma concentration [24, 28, 112]. The application of
each decision rule is called a stage in the DTR, and applying a DTR generates a trajectory
of data O1 , A1 , O2 , A2 , ..., OK , AK , OK+1 ; these are are represented in upper case to emphasize
that they are random variables which represent potentially noisy observations of a patient and
actions which depend on the observations. We define the history of the patient at stage j to
be H j = (O1 , A1 , O2 , A2 , · · · , O j−1 , A j−1 , O j ); this encompasses all information available for
decision-making at stage j.

Defining and Estimating Optimal DTRs
To define the performance of a decision rule (and of a DTR) we also define a reward Y j =
Y j (H j , A j , O j+1 ) which is a quantitative measure of success of the outcome that follows the
stage j action, coded so that higher values are preferable. The sum of the rewards achieved
over a single trajectory is called the return. Given this definition, the value of a DTR is given
by
 K

X 
V = E  Yk  ,
d

(5.1)

k=1

which is the expectation of the return if we follow DTR d. Typically, a DTR is defined to be
optimal if it achieves the highest possible value among those under consideration; this corresponds to the concept of maximizing utility or minimizing expected loss in statistical decision
theory [9].
There are different ways of estimating an optimal DTR [112]. One way, called “Q-learning”
relies on estimating the optimal Q function. We give an overview of Q-learning for DTRs here,
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and refer the reader to other sources for more detail [24]. The optimal Q function at stage
j < K is a function of the observed history h j and a proposed action a j given by
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opt
and Qopt
K (hK , aK ) = E[Y j (hK , aK , OK+1 )|HK = hK , AK = aK ]. The function Q j represents the

expected return if we choose action a j when history is h j and subsequently always choose
actions that are optimal, that is, give highest expected return. Given the optimal Q function, an
optimal DTR is given by choosing the action that maximizes it:
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(5.3)

The Q-learning algorithm proceeds by first estimating Qopt
K , often by acquiring a dataset
of tuples of the form (hK , aK , yK ) and regressing the yK on the hK and aK . The resulting Q̂opt
K
can estimate the expected reward for any choice of hK and aK . It is then used to estimate
QK−1 , which is in turn used to estimate QK−2 , and so on. This “backward induction” approach
emphasizes that the optimal decision rule at earlier stages depends on the decision rules at later
stages, and that they cannot in general be optimized independently.

5.2.2

Bayesian Models of Pharmacokinetics

In order to estimate the optimal Q functions, we need to be able to predict how a patient’s
concentration is likely to evolve over time in response to a hypothetical dose (action). Our
approach is to build a Bayesian model of patient pharmacokinetics that can use baseline clinical
information, as well as any available concentration measurements, to make tailored predictions
of future concentrations that are as accurate as possible given the model structure and available
data. The model is flexible in that it can condition on whatever information is available—for
example, if previous dose and measurement information is not available for a specific patient,
the model will rely on baseline information alone. If it is available, the model will use it to
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(hopefully) make improved predictions. This allows us to optimize both initial doses and later
dose adjustments after additional information about concentration is acquired.
Bayesian models have another key property that we use in our framework. Once they are
fit to data, and assuming the model is fit well, they are able to simulate the trajectories of
patients drawn from a distribution that is similar to the distribution of the data that the models were trained on, but in the simulated data, all variables—including normally-hidden PK
parameters—are fully observed. This allows us to conduct a form of internal validation where
we use the simulated patients to assess the relative benefits of different modes of static and dynamic personalization, because we can know for each simulated patient exactly what the effect
of any dose would be. This process is described in detail in the next section, where we present
our framework, and the details of the Bayesian model itself are provided in Appendix 5.8.

5.3

Framework

In this section, we present the components of our framework for assessing static and dynamic
personalization, including details for fitting a hierarchical Bayesian PK model to concentration
data from a cohort of patients, assessing the behaviour of Markov chains via diagnostics, and
using the Bayesian model to generate simulated data for evaluation. We then outline several
modes of static and dynamic personalization ranging from no personalization (every patient
gets the same dose) to a complex dynamic mode of personalization (estimation of the optimal
Dynamic Treatment Regime for dosing). Finally, we outline steps for assessing the benefits of
each mode of personalization.

5.3.1

Bayesian Modelling

The first step in our framework is to fit a Bayesian model that relates patient covariates and dose
to drug concentration as a function of time. For example, previous work [79] describes a hierarchical Bayesian model of apixaban pharmacokinetics, in which the clearance Cl (L/hour), time
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to maximum concentration tmax (hours), absorption time delay δ (hours), and ratio between the
elimination and absorption rate constants (α = ke /ka , a unitless parameter) are hierarchically
modelled. In our case study, we extend that model by regressing the latent pharmacokinetic
parameters on baseline clinical variables (age, sex, weight, and creatinine) to permit personalization. The model could equally well be extended with pharmacokinetic or biomarker information if the relevant theory and data were available for a particular use case. We detail our
hierarchical Bayesian pharmacokinetic model and provide sampler diagnostics in section 5.8.

5.3.2

Modes of Personalization & Assessment of Personalization

The second step in our framework is to identify modes of personalization that we wish to
evaluate. We classify these modes of personalization into two types: static and dynamic personalization.
Static modes of personalization seek to inform the dose at one point in time (usually treatment initiation) with the goal of eliminating the need for “trial-and-error” adjustments. We
consider two modes of static personalization in our case study:

1. One size fits all. This mode of personalization is not very personal at all. All patients
receive the same dose size at the onset of treatment (≈ 8.5mg taken twice daily). This
dose was selected so that the average value across patients was maximized.
2. Dose based on clinical variables. In this mode of personalization, the patient’s covariates, for example age, sex, weight, creatinine (a measure of kidney function) measurements are provided to the pharmacokinetic model. In other applications, genetic
information could also be provided should it be available. A dose size is then selected
using the model to maximize the value function conditional on these measurements.

Dynamic modes of personalization seek to personalize the initial doses but also the titration
process. We consider four modes of dynamic personalization for our case study:
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1. One size fits all initial dose and one dose adjustment. This mode of personalization
provides all patients the same dose to start, but requires a concentration measurement to
be made sometime in the future, which is then used to adjust the dose. For example, in
our case study, patients take their initial dose once every 12 hours with perfect adherence for five days, and, a sample is taken randomly in the second 12 hour period of the
fourth day. Our pharmacokinetic model conditions on this measurement, and the dose is
adjusted in order to maximize the value for another five days by updating our Bayesian
model with the measurement.
2. Initial dose based on clinical variables and one dose adjustment. Here, the initial
dose provided to the patient is determined by the patient’s clinical measurements. On
the second half of the fifth day, a concentration measurement is made at a random time.
The model is conditioned on this concentration and the dose is adjusted to optimize the
value.
3. Initial dose based on clinical variables and optimally-timed observation. Similar to
the previous mode of personalization, but the time at which the measurement is made
is under our control and tuned to maximize value. The time at which the sample is
taken can yield more or less information about particular parameters in the model, but
increases the burden by necessitating an additional constraint on when the observation
should be obtained. For example, measuring much later after the dose is taken yields
more information about the elimination rate constant ke than it does about the absorption
rate constant ka because later in time, the majority of the dose has been absorbed and is
now being eliminated by the body. In this mode of personalization, the initial dose and
the timing of the adjustment are optimized independently.
4. Optimal sequential dosing. The approach of this mode is the same as the previous
mode, except that the initial dose and the timing of the adjustment are jointly optimized
using Q-learning to maximize the value.
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We stress that these are just examples of some modes of personalization, and that we do not
mean that these modes should always be candidate modes for personalization, nor that they
are the only modes of interest. These modes may not be appropriate for all drugs across all
indications, and were selected in order to illustrate natural extensions and combinations of
static personalization with additional information collection. A strength of our approach is that
many possible modes of personalization may be considered depending on what is appropriate
for the use-case at hand.
Each simulated patient has their dose(s) selected under each mode of personalization. Since
the patients are simulated, we can compute what the return under the proposed dose(s) obtained
from each mode of personalization and compare the return achieved to the largest return theoretically possible (i.e. the return achieved were we to know the pharmacokinetic parameters
exactly when providing the initial dose, which is not possible in practice). The difference
between this optimal return and the actual return is called the regret. Comparing the regrets
achieved by different modes allows us to assess their relative performance, and helps us decide
which are most appropriate for a given personalized medicine problem.

5.4

Case Study

We present a case study of applying our framework to investigate the potential benefits of
static and dynamic personalization of apixaban dosing. Apixaban is a direct acting anticoagulant medication used to treat active blood clots occurring with deep venous thrombosis
or pulmonary embolism, or to prevent stroke in patients with atrial fibrillation. Prescribing
an apixaban dose that achieves blood concentrations within an optimal range is expected to
provide optimal treatment benefits while minimizing harms (e.g., serious bleeding). Clinical
variables measuring age, weight, and kidney function are routinely used for dosing, and female
sex, co-medications and genetic factors are known to contribute to higher circulating apixaban concentrations [45]. However, these variables only explain 35% of the pharmacokinetic
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Figure 5.1: Visual representation of the steps in our framework. A Using only clinical information, the model is used to select a dose that is expected to keep the patient in the desired range
for as long as possible. The blue ribbon indicates 90% credible interval for the latent concentration. B Some time later, the patient’s blood serum concentration is measured (black dot). C
The observation is incorporated into the model and a new dose is selected to keep the patient
in range for as long as possible. The red ribbon indicates 90% credible interval for the latent
concentration after adjusting the dose. D The black line indicates the true latent concentration
under each dose. Note the observation (black dot) is not on the black line (true concentration)
because there is measurement error, which the model accounts for.
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variability in apixaban, which serves as rationale for considering dynamic dose optimization
supported by post-initiation blood concentration monitoring.

5.4.1

Bayesian Modelling

To create the necessary model for apixaban personalization, we extend a previously proposed
one-compartment Bayesian pharmacokinetic model [79] to include fixed effects of covariates
on pharmacokinetic parameters in order to incorporate baseline clinical information (age, sex,
weight, and creatinine.) Full details of the model structure, fitting, and diagnostic checks are
provided in Appendix 5.8. We fit the model to previously-collected data on apixaban concentration [109] and then use the fitted model to simulate patients with known ”ground truth”
pharmacokinetic parameters as described previously. We then use this population of simulated
patients in our experiments to explore different modes of dose personalization and their relative
benefits.

5.4.2

Modes of Personalization

We consider the 6 modes of personalization as outlined in section 5.3. To evaluate these modes
of personalization, we generate 1000 simulated patients taking a dose of apixaban once every
12 hours with perfect adherence for a total of 10 days. The goal is to maximize the time spent
with blood concentration level between between 100 ng/ml and 300 ng/ml. We choose this
range as it is not so narrow that even optimal doses perform poorly, but not so wide that any
dose can achieve high reward. For static modes of personalization, the selected initial dose is
fixed over the 10 day period. For dynamic modes of personalization, some time in the second
12 hour period on the fourth day (between 108 and 120 hours after the initial dose), the simulated patient’s blood concentration is measured, and then at the start of the fifth day, the dose
is adjusted based on all the pre-dose clinical measurements plus the observed concentration by
incorporating the new information into the Bayesian model.
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Defining the Dynamic Treatment Regimes
To implement the two dynamic modes of personalization, we estimate DTRs with two stages
(the first five days, and the latter five days). For the dynamic personalization policies our
experiments, we develop a DTR for selecting the best dose for keeping a patient’s blood plasma
concentration within a desired range. In terms of the DTR, the system is the patient for whom
a dose is selected, the actions correspond to selection of dose sizes (and a time in the future to
sample the patient, should the DTR require that), and the reward is the proportion of time spent
within the desired concentration range. The trajectories we will use to estimate the optimal Q
functions are of the form

O1 , A1 , Y1 , O2 , A2 , Y2

(5.4)

The interpretation of a given trajectory is:
• O1 is any pre-dose clinical measurements of the patient. In our experiments, we consider
age in years, renal function (as measured by serum creatinine in mMol/L), weight in kilograms, and dichotomous biological sex (dummy coded so that male=1 and female=0).
We choose these variables as they are known to affect the pharmacokinetics of apixaban
[19].
• A1 is the initial dose to provide the patient. If the DTR allows us to specify a time in the
future at which to measure the patient’s blood serum concentration, then A1 is the dual
action of initial dose plus a time in the future at which to measure.
• Y1 is the proportion of time spent within the concentration range in the first five days.
• O2 is the pre clinical measurements of the patient plus the observed concentration made
on the fourth day.
• A2 is the dose adjustment
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• Y2 is the proportion of time spent within the concentration range in the final five days
after the dose adjustment.
The actions A j affect the reward Y j mediated by their effects on concentration. For example,
a larger dose will elicit larger concentrations which may put the patient in range for longer
(more reward) or take them out of range for some time (less reward). Thus, our reward function
can be thought of as a composition of the reward function and the concentration function. In our
experiments, we create a mesh of 2K times at which we can evaluate the latent concentration
and compute the reward function. Each stage in our DTR consists of K = 240 times (equivalent
to evaluating the latent concentration function every 30 minutes after ingestion). Let ci , i =
1...2K , be the ith latent concentration value at time ti . The reward function in the first stage is
K
1X
I(100 < ci (A1 ) < 300)
Y1 (H1 , A1 ) = Y1 (c1 (A1 ), . . . , cK (A1 )) =
K i=1

(5.5)

Here, I is an indicator function returning 1 if ci is between 100 ng/ml and 300 ng/ml and 0 else.
The reward function in the second stage is
K
1X
I(100 < cK+i (A2 ) < 300)
Y2 (H2 , A2 ) = Y1 (cK+1 (A2 ), . . . , c2K (A2 )) =
K i=1

(5.6)

Our stage 2 optimal Q function is then
"

#

Q2 (H2 , A2 ) = E Y2 (cK+1 (A2 ), · · · , c2K (A2 )) H2 , A2 ,
opt

(5.7)

and our stage 1 optimal Q function is
"

#

Q1 (H1 , A1 ) = E Y1 (c1 (A1 ), · · · , cK (A1 )) + max Q2 (H2 , a2 ) H1 , A1
opt

opt

a2

(5.8)

We seek to maximize the stage 1 optimal Q function to learn the optimal DTR for dosing
patients under the constraint we can measure them at most once and are limited to the aforementioned pre-dose clinical variables. The interpretation of stage 1 optimal Q function is as
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follows: Given the pre-dose clinical variables of the patient and a proposed initial dose and
measurement time, the stage 1 optimal Q function gives the expected proportion of time the
patient’s blood serum concentration is between 100 ng/ml and 300 ng/ml assuming that we
provide the patient with the best dose possible at the start of the 5th day. The decision rules
which choose A1 and A2 to maximize these functions constitutes the estimated optimal DTR.

5.4.3

Evaluating Modes of Personalization

We measure the performance of different modes in terms of regret, the difference between
theoretically largest possible return if the individual’s PK parameters were precisely known
and the achieved return by each mode of personalization. The results are shown in figure 5.2,
ordered from least amount of information and burden (top) to most amount of information and
burden (bottom) and colored by their personalization strategy (static or dynamic).
Modes of personalization which use less information have larger regret. The One Size
Fits All approach (which uses no information about the patient) performs worst with a median
regret of 0.145. The distribution of regrets for this mode is right skewed with some exceeding
0.95, meaning the patient could have been in range for nearly the entire time if the correct PK
parameters were known, but the mode selected a dose which failed to put the patient in range.
The Clinical Variables mode nearly cuts the regret in half, achieving a median regret of
0.086 with smaller right skew. Modes which use observed concentration information (Clinical
Variables + One Sample, Optimal Sampling Time, and Optimal Sequential Dosing) lead to
slightly lower median regrets (0.075, 0.076, 0.079 respectively) as compared to the Clinical
Variables mode.

5.5

Limitations

Our framework relies on the quality of the Bayesian model used to predict plasma concentrations. The data required to construct a high quality Bayesian model of pharmacokinetics
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Figure 5.2: Boxplots of the regret – the difference between the largest possible return and the
achieved return for each of the 1000 simulated patients. patients who achieve a return close to
their maximum possible return have a regret near 0, while patients who achieve a return less
than their maximum possible have larger regrets, with the largest possible regret being 1.
require multiple observations of a single patient over an extended time, preferably over multiple well timed doses with near perfect adherence. Obtaining such data requires well organized
efforts and is high burden for both investigators and participating subjects. This makes acquiring a robust Bayesian model for use in dose personalization difficult. For this reason,
our framework is not intended to replace prospective evaluation of personalized medicine programs; rather it is intended to estimate relative performance given existing evidence so that the
most promising modes of personalization can be identified for potential implementation and
further study.

5.5.1

Related Work

Individualized Dose Rules Much recent work on individualized dose rules (also sometimes
called personalized dosing rules, or personalized treatment rules, or personalized treatment decisions) focuses on estimation of the value function and use of Q-learning or similar techniques
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for estimation of the optimal policy. Chen et. al [26] extended an application of O-learning
from Zhao et. al [125] to the case with continuous treatment values (i.e. doses). Laber and Zhao
[58] proposed an approach to estimating optimal personalized treatment rules using decision
trees, placing emphasis on their interpretability. Li et.al [60] estimate individualized dose rules
by directly balancing risks of efficacy and outcomes using a large number of biomarkers and
patient covariates and an ℓ1 penalty. Park et. al [80] demonstrate a semi-parametric approach
to estimating the dose by covariate interaction effects on treatment response and demonstrate
this approach on Warfarin dose outcomes with clinical and pharmacogenetic data. Rich et.
al [86] design a sequential multiple assignment randomized trial for optimal dose selection,
and demonstrate their design by simulating data from a pharmacokinetic model based on Warfarin. They contrast Q-learning and G-estimation for estimating the parameters of various value
functions which incorporate various different sources of information into the individualization
process.
In many of these studies, the value function must be estimated, often with a suitably flexible
regression method. Because the value function must be estimated, there is a risk of model
misspecification. In our work, we need not estimate the value function because it is a function
of latent concentrations. We integrate our uncertainty over these latent concentrations and pass
them to our value function directly. This avoids possible misspecification of the value function,
allowing investigators to focus their modelling on the pharmacokinetics.

5.6

Conclusions

As expected, modes of personalization that use more information result in lower regret (larger
achieved rewards.) The static Clinical Variables mode balances relatively low implementation
burden with high reward. However, there is right skew in the distribution of regret, with some
‘outliers’ who are at risk of obtaining less than half of their best possible return. If avoiding
this risk is important, the Clinical Variables + One Adjustment mode may be preferable, even
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though it imposes additional burden.
The Optimal Sampling Time and Optimal Sequential Dosing modes use the same information as Clinical Variables + One Adjustment, but impose more burden on the patient and
clinic. Both require samples be taken at specified times, and the second uses a more complex
optimization procedure. Neither of these improved performance beyond the simpler modes in
our study. There are two characteristics of our study that may explain this result. First, the
clinical variables used are known to affect the pharmacokinetics of apixiban and are useful for
predicting concentrations for static personalization, hence their use alone makes it possible to
choose good doses. In other settings where clinical variables are not as predictive, we would
expect dynamic personalization to have a bigger advantage. Second, the elimination rates ke
in our study were relatively high. This means that the effect of an initial dose on levels at the
time subsequent doses are taken (i.e., a day later) is relatively small, so that doses can be optimized largely independently. If this were not the case, optimization using Q-learning would
be expected to be more important to ensure that initial doses were not too large to successfully
adapt later.

5.7

Implications

Any decision to implement personalized medicine must assess the costs and benefits of doing
so. Despite the potential for personalized medicine to reduce health care costs [62, 97], the
cost of patient testing and monitoring, personnel, and training required to operate a personalized medicine clinic carry a burden, and it is not yet clear in what circumstances personalized
medicine is cost effective. In their 2019 scoping review of personalized medicine cost effectiveness, Kasztura et al [56] found that willingness-to-pay thresholds vary wildly from country to
country (citing that cost per quality adjusted life year (QALY) for some modes of personalized
medicine range from $20,000 USD per QALY in Europe and the United Kingdom to $200,000
USD per QALY in the United States). This high variability means the burden required for start
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up may result in a positive return on investment in some areas but not others. This variability
should prompt would be adopters to more closely examine whether taking on the initial burden
is worth the result.
Others have noted that much work on personalized medicine has not centred on the needs,
constraints, and utilities of the patient [90, 29]. Patients can be burdened by frequent followup
for clinical measurement (as in the case with warfarin), be burdened by costly expenses related to obtaining care, or may be more risk adverse/tolerant than the “typical” patient. As
an example, transportation has been found to be a large financial burden for patients receiving
cancer treatment [51], and continues to burden patients, with a 2020 study finding that the cost
of parking alone can climb as high as $1600 over the course of treatment in the United States
[59]. Additional visits to a clinic have the potential to further burden patients by requiring
them to miss a day of work, and find means of childcare during their absence (if necessary).
Incorporating patient preferences and reducing the burden of personalization on the patient
can result in sustained adherence [31], thereby increasing effectiveness and further preventing
adverse events.
The complexity of balancing these burdens means that implementation decisions made at
the organizational level need to attend to a broad array of evidence and contextual factors.
Know4Go [66] is one framework for explicitly considering factors from expanded domains
of influence surrounding adoption of new technologies/interventions in a healthcare setting
(like a clinic or hospital). These expanded domains of influence include: social, legal, ethical,
environmental/institutional, political, entrepreneurial/innovative, research opportunity, and reversibility factors in conjunction with objective evidence of benefits versus risks, systematic
review, and costs. Broadly, once evidence has been synthesized through systematic review
and/or meta-analysis, the evidence is contextualized to local healthcare system perspective.
Evidence is converted onto a benefit scale, derived from the number of patients likely to benefit from adoption of the technology/intervention. Budget impact of the adoption is estimated
using costing data from the hospital/clinic, and new technologies can be triaged according to
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their impact and cost.

Policy decisions around personalization are complex. They carry burden for health systems
and patients that vary widely by context. While there are frameworks like Know4Go for navigating these decisions, applying them requires quality evidence for the potential benefits of
different kinds of personalization, even for deciding on potential pilot studies. Our framework
can produce evidence for the potential effectiveness of a range of modes of personalization to
inform organization-level decisions surrounding the investigation and implementation of personalized medicine programs that reduce cost, respect burden, and improve outcomes.

5.8

Appendix

Bayesian PK Model Details

The Bayesian model used to predict personalized concentration in response to dose, which we
refer to as M1 , is
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yi, j ∼ Lognormal Ci (t j ), σ2y
σ2 ∼ Lognormal (0.1, 0.2)
D · F k · k 

e,i
a,i

i
−ka,i (t j −δi )
−ke,i (t j −δi )


·
e
−
e
t j > δi


 Cli
ke,i − ka,i
Ci (t j ) = 




0
else
ke,i = αi · ka,i
ka,i =

log(αi )
tmax,i · (αi − 1)

(5.9)
(5.10)

(5.11)

(5.12)
(5.13)

δi ∼ Beta(ϕ, κ)

(5.14)

logit(αi )|βα , σ2α ∼ Normal(µα + xTi βα , σ2α )

(5.15)

log(tmax,i )|βtmax , σtmax ∼ Normal(µtmax + xTi βtmax , σ2tmax )

(5.16)

2
log(Cli )|βCl , σCl ∼ Normal(µCl + xTi βCl , σCl
)

(5.17)

p(ϕ) ∼ Beta(20, 20)

(5.18)

p(κ) ∼ Beta(20, 20)

(5.19)

p(µCl ) ∼ Normal(log(3.3), 0.152 )

(5.20)

p(µtmax ) ∼ Normal(log(3.3), 0.12 )

(5.21)

p(µα ) ∼ Normal(−0.25, 0.52 )

(5.22)

p(σy ) ∼ Lognormal(log(0.1), 0.22 )

(5.23)

p(σCl ) ∼ Gamma(15, 100)
p(σtmax ) ∼ Gamma(5, 100)
p(σα ) ∼ Gamma(10, 100)

(5.24)
(5.25)
(5.26)

p(βCl,k ) ∼ Normal(0, 0.252 ) k = 1...4

(5.27)

p(βtmax ,k ) ∼ Normal(0, 0.252 ) k = 1...4

(5.28)

p(βα,k ) ∼ Normal(0, 0.252 ) k = 1...4

(5.29)
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βα

βCl

βtmax

Age -0.08 (-0.27,0.1) 0.01 (-0.06,0.08) -0.01 (-0.1,0.08)
Creatinine -0.06 (-0.25,0.14) 0.02 (-0.05,0.09) -0.05 (-0.14,0.04)
Sex -0.2 (-0.53,0.15) 0.39 (0.23,0.54) -0.01 (-0.18,0.15)
Weight 0.32 (0.11,0.55)
0.2 (0.12,0.27)
0.09 (0.01,0.18)
Table 5.1: Posterior means for coefficients for each covariate in our pharmacokinetic model.
In parantheses are 95% credible interval estimates.

Here, normal distributions are parameterized by their mean and variance, lognormal distributions are parameterized by the mean and variance of the random variable on the log scale,
and gamma distributions are parameterized by their shape and rate. The µ in the model above
represent population means on either the log or logit scale, the β are regression coefficients
for the indicated pharmacokinetic parameter, the sigmas are the population level standard deviations on the log or logit scale, δ is aparameter which relaxes the assumption that the dose
is absorbed into the blood immeditately upon ingestion, F is the bioavailability of apixiban
(which we fix to 0.5 [19]) and D is the size of the dose in milligrams. All continuous variables
were standardized using the sample mean and standard deviation prior to being passed to the
model.

Once fit, M1 can be used to predict the pharmacokinetics of new patients, using the patient’s covariates as predictors. To do so, the marginal posterior distributions for µCl , µtmax , µα ,
βCl , βtmax , βα , σCl , σtmax , σα , and σy must be summarized. We use maximum likelihood on the
posterior samples to summarize the marginal posterior distributions. We model the population means and regression coefficients as normal, and the standard deviations as gamma. The
maximum likelihood estimates are used to construct priors for a new model, which we call
M2 . We construct M2 so as to be able to predict plasma concentration after multiple doses (of
potentially different sizes) administered over time, and remove the time delay (δ) to simplify
our simulations. Model priors for M2 are then
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p(µCl ) ∼ Normal(0.5, 0.04)

(5.30)

p(µtmax ) ∼ Normal(0.93, 0.05)

(5.31)

p(µα ) ∼ Normal(−1.35, 0.13)

(5.32)

p(σCl ) ∼ Gamma(69.15, 338.31)

(5.33)

p(σtmax ) ∼ Gamma(74.96, 349.56)

(5.34)

p(σα ) ∼ Gamma(10.1, 102.07)

(5.35)

p(βCl,1 ) ∼ Normal(0.39, 0.082 )

(5.36)

p(βCl,2 ) ∼ Normal(0.19, 0.042 )

(5.37)

p(βCl,3 ) ∼ Normal(0.02, 0.042 )

(5.38)

p(βCl,4 ) ∼ Normal(0.01, 0.042 )

(5.39)

p(βtmax ,1 ) ∼ Normal(−0.01, 0.082 )

(5.40)

p(βtmax ,2 ) ∼ Normal(0.09, 0.052 )

(5.41)

p(βtmax ,3 ) ∼ Normal(−0.05, 0.042 )

(5.42)

p(βtmax ,4 ) ∼ Normal(−0.01, 0.042 )

(5.43)

p(βα,1 ) ∼ Normal(−0.19, 0.172 )

(5.44)

p(βα,2 ) ∼ Normal(0.33, 0.112 )

(5.45)

p(βα,3 ) ∼ Normal(−0.06, 0.12 )

(5.46)

p(βα,4 ) ∼ Normal(−0.09, 0.12 )

(5.47)
(5.48)
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For our experiments, we generate the pharmacokinetic parameters of 1000 simulated patients from the prior predictive model of M2 . Bayesian models are generative models, meaning
they can generate pseudodata by drawing random variables according to the model specification going from top (model priors) to bottom (model likelihood). To do so, we begin by resampling 1000 tuples of age, sex, weight, and creatinine from the dataset used to fit M∞ . We
sample one draw of r µCl , µtmax , µα , βCl , βtmax , and βα from their respective prior distributions in
M2 . The values of these parameters remained fixed for all 1000 patients. Conditioned on the
values of these mus and betas, we compute the expectation of the population distribution for
each pharmacokinetic parameter by computing µCl + xT βCl , µtmax + xT βtmax , µα + xT βα , where
xT is the resampled tuple. From the prior distribution of M2, we sample one draw ofσCl , σtmax ,
σα , and σy . These remained fixed for all 1000 patients. Using the previously computed expectations and σ, we sample 1000 tuples of pharmacokinetic parameters, one for each of the
simulated patients. The clearance rate and time to max concentration were sampled assuming
a lognormal distribution. Alpha was sampled using a logitnormal distribution. The pharmacokinetics can then be determined conditional on the pharmacokinetic parameters. Each of
simulated patients’ pharmacokinetic parameters remained fixed through the experiments. We
simulate the latent concentration using C(t) as written in M2 , and can simulate observed concentrations by drawing a sample from a lognormal distribution with mean ln(C(t)) and standard
deviation σy

We use Stan, an open source probabilistic programming language, for fitting our Bayesian
models via Hamiltonian Monte Carlo (a Markov Chain Monte Carlo technique) and computing
markov chain diagnostics. Twelve chains are initialized and run for 2000 iterations each (1000
for warmup allowing the Markov chain the opportunity to find the correct target distribution
and 1000 to use as samples from the posterior).
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Diagnostics For Bayesian Models Fit Via MCMC
Once the form of the model is specified, creating simulated patients or estimating the PK parameters of a real patient requires computation of or sampling from the posterior distribution of
the relevant variables given the relevant data. However, exact computation of the posterior distribution is intractable for all but very simple models, so Markov chain Monte Carlo (MCMC)
techniques are often used to approximate the expectations with respect to the posterior distribution. Presently, the gold standard for generating samples from the posterior is Hamiltonian
Monte Carlo (HMC), which works by generating a sequence of samples that “explores” the
posterior distribution by solving a system of ordinary differential equations which describe the
motion of an imaginary particle as it rolls along the surface of the log posterior density. Many
implementations of HMC come with diagnostics which monitor the behaviour of the Markov
chains that are used to generate samples and help to ensure that they are representative of the
posterior distribution. That these Markov chains behave well is crucial, as any inferences about
or from the model are obtained from samples generated by the chains. To assess the quality of
the Markov chains, several diagnostics are commonly used including: number of divergences,
the Gelman-Rubin convergence diagnostic, and effective sample size [12].
In practice, several Markov chains are used simultaneously to generate samples from the
posterior. The chains are assessed with within-chain and between-chain diagnostics. First,
individual chains may sometimes diverge. A divergence in a Markov chain indicates that the
HMC Markov chain has encountered a region of high curvature in the posterior distribution
which cannot be adequately explored. Consequently, Monte Carlo estimators of any expectations can be biased due to incomplete exploration of the posterior distribution. It is important
that none of the Markov chains generated by HMC display a divergence, and that many chains
(typically 4 or more) are initialized and are allowed to explore the posterior distribution.
Having ensured that no chains are diverging, a group-level diagnostic is used to assess
whether all chains have converged to the same limiting distribution. The Gelman-Rubin (sometimes called R̂) convergence diagnostic is designed to detect if the Markov chains have con-
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verged to the same distribution by measuring the within-chain variance to the between chainvariance. In practice, 1.05 < R̂ indicates that there is poor mixing of the Markov chains and
inference from the samples should not be performed lest the Monte Carlo estimators are biased
by this poor mixing.

Even if the chains do not exhibit divergences and arrive at the same limiting distribution,
the Markov chains could still exhibit high within-chain correlation, thereby increasing the uncertainty of estimation of key posterior quantities such as means, variances, or quantiles [17].
The effective sample size is a measure of how much the within chain autocorrelation increases
uncertainty estimates. Presently, the guidance is that the effective sample size ratio should be
larger than 100 × (number of chains) [116].

In addition to monitoring divergences, Gelman-Rubin convergence diagnostics, and effective sample sizes, the model should be evaluated against existing domain knowledge. Evaluating that the model has learned appropriate behaviour (e.g. that as one quantity increases,
another should decrease) can be performed by plotting model predictions. Additionally, posterior predictive checks – generating synthetic data from the model’s posterior distribution and
comparing against the real data – can be performed to ensure the model is not generating data
which are physically impossible or completely unrealistic. Once the model is fit, important
diagnostics indicate no pathological behaviour, and the model is deemed to fit the data sufficiently well, the model can then used to generate synthetic pharmacokinetic data for use in
experiments to compare different forms of personalization. Each generated data point may be
thought of as one synthetic patient, with observed covariates and observed pharmacokinetic
parameters. These parameters, which are never observed in real data, allow us to compute the
effects of any dosing decisions (which are made without direct knowledge of the parameters),
and thus allow us to evaluate the performance of different modes of personalized dosing on the
sampled population.
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Figure 5.3: Random effects estimates for clearance Cli and 95% credible intervals (left). Random effects estimates are colored by patient sex. Prior to adjusting for covariates, a general
trend in weight can be seen in the random effects. Patients who are heavier tend to have larger
random effect, and males tend to have larger random effects than females of the same weight.
Patterns such as these indicate that weight and sex can be used to explain variation in the random effects. After adjusting for sex and weight (right), the random effects have no discernable
pattern.
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Bayesian Model Diagnostics for Case Study
We fit our model to real pharmacokinetic data using the open source probabalistic programming
language, Stan [37]. Stan monitors several Markov chain diagnostics, none of which detected
problematic Markov chain behavior, which indicates that Stan’s sampling algorithm was able
to converge (0 divergences, all all Gelman-Rubin diagnostics¡1.01, all effective sample sizes ¿
2600).
The inclusion of covariates in the model results in a better fit than excluding them. Shown
in figure 5.3 are the estimated random effects for the clearance pharmacokinetic parameter of
each patient as a function of weight. Patient sex is indicated by color, the overall trend is shown
in the black dashed line. Failing to include patient sex and weight results in males having on
average a larger random effect than females of the same weight, and heavier patients having
a larger random effect than lighter patients. When covariates are added into the model, the
variation in the random effects attenuates, resulting in closer alignment to model assumptions.
A better fit to the data means data generated from the model may be closer aligned with the
true data generating process.
Examining the posterior distributions of the regression coefficients provides further insights
into the relationships between covariates and pharmacokinetics. Greater patient weight is associated with an increase in the expected value of alpha (which is used to compute the elimination
and absorption rates in the first order one compartment PK model. The parameter α is the ratio of how fast the drug exits the central compartment how fast the drug enters the central
compartment) which impacts the time to maximum concentration after each dose. There is an
estimated effect of sex on α (males have smaller alpha than females, meaning the drug leaves
their central compartment slower or enters the central compartment quicker), however the uncertainty is large (estimated effect -0.2 on the logit scale, 95% credible interval -0.53 to 0.15).
See section 5.8 in the Appendix for a full summary of the regression coefficients.
Model training error is comparable between the two models; the model without covariates
achieves an average error of 8.31 ng/ml as measured by root mean squared error. The model
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with covariates achieves a root mean squared error of 8.36 ng/ml. Estimates of concentration
uncertainty remain similar between the two models as well. We conclude the inclusion of
covariates in the model improves model inferences but does not substantially improve the fit of
the model in this case.
While prediction error and concentration uncertainty are comparable between the two models, the most important differences are between inter-individual uncertainty. The inclusion of
the covariates explains variation between individual pharmacokinetic parameters, hence the
between patient variability σCl , σtmax and σα are smaller in the covariate model as opposed to
the no covariate model. This uncertainty effects decision making, as the no covariate model is
more uncertain about the pharmacokinetics of new patients.

Chapter 6
Pooling Pharmacokinetic Information
Using Hierarchical Models
This chapter represents joint work with Drs. Simon Bonner and Dan Lizotte. I am the primary author of this work and was responsible for model design, implementation, as well as
writing the manuscript. Drs. Bonner and Lizotte participated in conception and planning, and
interpretation of research as well as critical review of the drafted materials.
The motivation behind this chapter comes from the observation that while our clinical pharmacology partners had at least two datasets on apixaban (both used in this study), only one was
used to study the effects of novel predictors on apixaban concentrations. Additionally, my earlier contributions towards studying effects of predictors on apixaban pharmacokinetics relied
on the use of linear models. As is described in the sections that follow, the use of that approach is acceptable under certain circumstances but could be further improved by modelling
the pharmacokinetics directly.

6.1

Introduction

One goal of personalized medicine is optimized dosing of drugs for individuals [70]. When
considering optimal doses, a thorough understanding pharmacokinetic (what the body does to
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the drug) and/or pharmacodynamic (what the drug does to the body) effects are crucial. To
this end, models describing the mediation of pharmacokinetic/pharmacodynamic effects via
clinical, genetic, and lifestyle factors have an important role in deciding which patients should
get what dose. Models of this nature are sometimes published by research teams collaborating
with drug manufacturers using data from clinical trials.
Independent investigators can find themselves in a situation in which data collection from
a particular population of interest is achievable. If the data come from practice (e.g. a personalized medical clinic), there may be questions about how new variables not previously studied
in clinical trials affect the pharmacokinetics/pharamcodynamics of a particular drug. Running
large studies in order to examine the effects of these new variables, or discover effects of other
variables, may be unrealistic due to a variety of constraints. Consequently, investigators must
think about how best to model the pharmacokinetics, for use in decision making and exploration, using the data available to them.
The oral anti-coagulant apixaban provides an illustrative example. Pharmacokinetic models have been previously published [27, 113] in collaboration with the drug’s manufacturer
using data from clinical trials. These studies identified age, sex, body weight, renal function,
patient race, and CYP3A4 inhibitors as modulators of apixaban pharmacokinetics [27], though
according to authors the effects of some of these variables were not large enough to require
clinical dose adjustment. However, even after adjusting for the aforementioned factors, concentrations of apixaban in real life applications have been observed to be larger than what was
reported in clinical trials [106], raising questions as to the optimal dosing of apixaban for patients in different settings. Additionally, recent research has indicated appropriateness of dose
adjustment criteria are unclear [118], citing there is no reduction in safety associated with an
increased exposure to apixaban in patients above 75 years of age, below 60kg of body weight,
and eGFR (the rate at which the kidneys filter the blood) lower than 50 mL/min. The uncertainty regarding dosing criteria and additional variability in concentrations in day to day use
suggests that, while previously published models may be internally valid, these models may
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not be representative of all populations in which apixaban is to be applied. That is to say, the
models may lack a degree of external validity, thus supporting the idea that pharmacokinetic
models may need to be tailored for specific populations of interest. When viewed through a
Bayesian lens, the previous modeling work can act as an informative prior on various pharmacokinetic/pharmacodynamic measures. Creating new models for populations of interest is then
more of a ”fine tuning” than an all together new approach. Pharmacokinetic models for use in
a specific population may then have two goals: to adjust doses for a specific population, and/or
to explore how additional variables (for example, concomitant medications) not included in the
previous studies affect particular parts of the pharmacokinetics of apixaban.
This study seeks to demonstrate how investigators can fit similar models to their pharmacokinetic data with the aim of accomplishing the goals of accurate modelling of pharmacokinetics and exploration of effects of new variables. We use apixaban as a specific example, but
our methodology can be generalized to other drugs for which pharmacokinetics are of interest.
Importantly, we only focus on pharmacokinetics since blood plasma levels correlate closely
with the pharmacodynamic effect of apixaban [19, 114, 33, 34]. Our approach leverages a
Bayesian methodology to building pharmacokinetic models so that we may incorporate prior
information from previous studies. Additionally, we describe how investigators can use all
relevant data available to them to fit these models and make inferences, even if the data are not
from controlled studies or if some patients are sampled once(sparsely sampled) while others
are sampled many times (repeatedly sampled). Also, we show how sparsity inducing priors can
be applied to new variables in order to explore how those variables may effect apixaban pharmacokinetics, encouraging negligible effect sizes but allowing for large effects to be detected
at the cost of a small amount of bias. We present a small simulation study to demonstrate how
smallest meaningful effects can be detected through these priors as a function of sample size.
Finally, we use an open source Bayesian language to develop our models, making our code
freely available. Previous models are constructed in a proprietary software tool set, which can
present a barrier for some. Creation of these models in a free tool removes a barrier to research,
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making these methods more widely available.

6.2
6.2.1

Background
Apixaban

Apixaban is a direct acting oral anti-coagulant often prescribed for prevention of stroke and
systemic embolism in patients with atrial fibrillation (AF) [1, 19]. Studies as recent as 2019
have reported excess variability in observed apixaban plasma concentrations in patients with
AF [106]. Since apixaban plasma concentrations correlate closely with anti-coagulation, excess variability in these concentrations may mean increased risk of bleeding. These findings
have raised questions towards the optimal dosing of apixaban in older adults with AF encountered outside of clinical trials. Additional research into determining factors which explain this
excess variability beyond known clinical factors [45] has consequently begun.

6.2.2

Variable Selection

Existing studies into pharmacokinetic modelling often use variable selection methods (e.g.
variants of stepwise selection, including fitting all submodels [27, 113]) when faced with the
determining which variables effect the pharmacokientics. Many studies have noted that these
techniques result in bias away from the null [121], exaggerated precision [4], inaccurate or
uninterpretable p−values due to inability to properly incorporate uncertainty in the selection
process [46], and can fail to select the ”true” model with high confidence even when modelling
assumptions are consistent with the true data generating process [98]. Hence, even in the
best case scenario where the selection procedure identifies the correct variables, the resulting
estimates may not be reliable. Results from these studies methods make a convincing argument
to avoid selection methods all together.
Variable selection methods are intended to answer the question ”which variables are im-
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portant in modelling the outcome”, and although studies have demonstrated deficiencies with
variable selection, they often do not provide an alternative answer. From a Bayesian perspective, selection to include a variable in or out of a model defines a sort of prior on the parameter
value; there is a strong preference for a null effect estimate unless the data provide sufficient
evidence for free estimation of that effect. Efforts to operationalize this prior structure in terms
of Bayesian inference have lead to a wide variety of sparsity inducing priors, which include
spike and slab priors [69], and horseshoe [23] and Finnish horseshoe priors [82]. These approaches admit that while unlikely that the effects of unimportant variables are exactly 0, they
may be small enough to be negligible. These priors place the majority of their probability mass
near 0, encouraging small effects to be estimated as something negligibly small, but allow for
large effects to be identified at the cost of a small amount of bias.
Bias towards a null effect can be acceptable when the goal is exploration and prediction.
When studies are small, the resulting estimate of effects can be high variance. In order for
an effect to be detected, it must be sufficiently large (so as to reject the null for example in a
Frequentist framework). However, in replication the estimated effects may attenuate and be
estimated to be smaller than previous estimates due to regression to the mean. In these cases,
bias towards can be acceptable because we are ”pre-shrinking” estimates. The bias pulls the
estimates towards the null, much like regression to the mean might. In this way, the initial
estimate may be closer to the true estimand.
To this end, we present a simulation study in which we use a sparsity inducing prior to
estimate the effect of a concomitant medication on apixaban pharmacokinetics. In particular,
the medication is assumed to inhibit a particular gene important in the elimination of apixaban,
making the bioavailability or half-life larger. We place a double exponential (or Laplace) prior
on the effect of the concomitant medication, as well as a prior on the parameter for the Laplace
distribution. This is similar to putting a LASSO penalty on the effect as well as a prior on the
LASSO penalty strength [108]. Although our simulation only has a single variable of interest,
many variables can be used with this prior structure.
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For our simulation, we generate data from the posterior of a previously fit model. We

simulate 10 datasets from a pre-specified number of repeatedly sampled patients (we examine
5, 10, 20, 30, 40, and 50 repeatedly sampled patients) haven taken their first dose of the drug
with a pre-specified and fixed effect of a concomitant medication on the bio-availability of
the drug. We assume that investigators can sparsely sample patients more easily, and so we
simulate 10 times more sparsely sampled patients who have already achieved steady state. We
do this so as to more closely resemble real life scenarios in which patients come into a clinic
for a plasma measurement having already been on the drug for sometime. We examine effects
of 0, 0.125, 0.25, 0.5, 1.0, and 1.5 on the logit scale (we use the logit scale since bioavailability
is constrained to be between 0 and 1).

6.2.3

Why Is a Hierarchical Model Needed?

In this paper, we propose a pooling of both sparsely and repeatedly sampled data in a single
model. Pooling information is not a new approach, and reasonable arguments could be made
to use simpler models. After all, if the sparsely sampled data models a continuous outcome
as a function of covariates, why would investigators use a complex model when something
simple like linear regression (or linear regression on log concentrations) may be sufficient?
While simpler approaches and criticisms of using unnecessarily complex models are valid,
both linear modelling and mixed effects models for pooling suffer from important drawbacks
in the case when attempting to combine sparsely sampled and repeatedly sampled data from
different studies. We examine those drawbacks below.
Linear regression can be, and has been [45, 115], used to model apixaban concentrations as
a function of time and other covariates using sparsely sampled data. When certain criteria are
met, there is good reason to do so. The concentration profile, C(t), from a first order absorption
with linear elimination pharmacokinetic model looks like

C(t) =


F · D ke · ka  −ka t
e − e−ke t
Cl ke − ka
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Here, D is the dose size, F is the bioavailability of the drug, Cl is the clearance rate, and ka and
ke are absorption and elimination rate constants respectively. The assumption that ke < ka is
typically made in order for the model to be identified [119, 93]. The elimination phase occurs
when t is sufficiently large, resulting in C(t) being approximately exponential and log(C(t))
being linear in time on the log scale with slope −ke . The assumption that measurement error is
additive on the log scale facilitates use of linear regression.
This approach is common in pharmacokinetics when estimating the elimination rate but
suffers from three important drawbacks generally. First, the elimination rate is not allowed to
vary as a function of known factors which effect elimination rate, such as kidney function. This
can be ameliorated by specifying an interaction between time and those covariates known to
effect elimination rate (though this has not been done in all studies [45]). Second, an exponential approximation is only appropriate when time is sufficiently large. Clearly, the exponential
approximation breaks down near t = tmax = log(ka /ke )/(ka −ke ) and is completely inappropriate
in the absorption phase when t < tmax . This affects estimates of max concentration in an appreciable way, resulting in an upward bias in estimates of Cmax . Additionally, because tmax is not
modelled per individual, estimates of Cmax must rely on a point estimate of tmax . This results
in uncertainty estimates of Cmax which may be too narrow for a given individual. Finally, the
effects of covariates on other aspects of the pharmacokinetcs are undetermined. Assuming a
linear model is used to model concentrations on the log scale, we find



log(C(t)) = log(D) + log(F) − log(Cl) + log(ke ) + log(ka ) − log(ke − ka ) + log e−ka t − e−ke t
≈ log(D) + β0 + β1 t

when tmax ≪ t .

Here, β0 = log(F) − log(Cl) + log(ke ) + log(ka ) − log(ke − ka ). If covariates are included in
the model, then although changes in log concentration may be accurate (in so far as the sign of
the change in log concentration is concerned), where that change occurs is under determined.
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Did concentration increase because bioavailability (F in the log linear model) increased, or
was it because the clearance rate (Cl in the log linear model) decreased? We can’t say for
certain from this model. In order to determine if a change in concentration was due to an
increase/decrease in a pharmacokinetic parameter, each pharamacokinetic parameter must be
modelled as functions of covariates. How salient these drawbacks are is up to the investigator,
but if any of them are important to decision making for personalized medicine then a linear
model will not be appropriate.
Mixed effects models can be used to pool information from many datasets. Meta-analysis is
perhaps the most prevalent example of this approach. A typical example may be pooling data
from studies conducted using similar protocols across multiple centres. Ideally, the data are
collected under similar protocols, making assumptions regarding the likelihood and exchangeability of appropriate units tenable. In the scenario we describe, where information from at
least two studies with different protocols are to be pooled, we believe a mixed effect model
specifying between study variation is not appropriate due to subjects not being exchangeable
between studies. Recall, a sequence of random variables θ1 , . . . , θn is said to be exchangeable
if their joint density p(θ1 , . . . , θn ) is invariant permutations of the indices (1, . . . , n) [35]. If no
other information, other than observed data, is available to distinguish any of the θ j from any
others, and no ordering or grouping of parameters can be made, one must assume exchageability of the θ. In the scenarios we describe, we do have additional information which can
be used to distinguish the θ. In particular, sparsely sampled data will have a larger estimated
residual error than repeatedly sampled data. This is because the residual variance is a combination of within and between subject variation. There are then two residual variances to be
estimated: one for the repeatedly sampled data and one for the sparsely sampled data. When
pooling sparsely sampled and repeatedly sampled data together, individuals within studies are
exchangeable because of the common residual variance within study. However, subjects are
not exchangeable between studies because permutations of the subject indices fail to account
for which subject should be associated with which residual error.

6.3. Bayesian Model

6.3
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Bayesian Model

Our model specifies a population level effect of covariates (age, sex, weight (kg), serum creatinine (µmol)) on patient clearance, time to max concentration, and the ratio between absorption
and elimination rates (a unitless parameter we refer to as α). These effects are shared between
all populations, allowing information from one dataset to partially inform model fit on the
other. We also include a population level effect of concomitant amiodarone on bioavailability of apixaban. We fit our model using Stan [37], an open source probabilistic programming
language with interfaces to Python, R, Stata, Matlab, and more.
Let s = 1 . . . K denote the number of studies being pooled together. Each study has j =
1 . . . N s subjects, whom are observed at times ti for i = 1 . . . T j . For sparsely sampled data,
T j = 1, meaning we have only one sample per subject. For repeatedly sampled data, 1 < T j ,
meaning we have multiple measurements from the same subject. In our data, we use K = 2
studies. There are N1 = 36 subjects in our repeatedly sampled data, and N2 = 402 subjects in
our sparsely sampled data. The repeatedly sampled subjects are each sampled T = 8 times.
Our model assumes there are population level effects of each covariate on the pharmacokientic parameters, and that the distribution of pharmacokinetic parameters given covariates x j,s
from subject j in study s are the same between studies. Let θ j,s be a vector of pharmacokinetic
parameters for subject j in study s. In our model, θ j,s is comprised of subject clearance rate,
time to max concentration, ratio between elimination and absorption rates, and bioavaiability
respectively θ j,s = (Cl j,s , tmax, j,s , α j,s , F j,s ). Our model is depicted as a Bayes net in Figure 1.
We estimate two non-pharmacokientic parameters from our data as well. Let δ j,s be the
time delay between ingestion of the bolus dose and absorption into the blood stream, and
let c0, j,s be the initial concentration of apixaban in the blood stream at the time of ingestion.
The time delay δ can not be estimated from the sparsely sampled data because only a single
measurement was taken, but can be estimated from the repeatedly sampled data. Therefore
we assume δ j,2 = 0 ∀ j. Additionally, sparsely sampled patients are assumed to be in steady
state and therefore have a non-zero initial concentration of apixaban in their blood at the time

96

Chapter 6. Pooling Pharmacokinetic Information Using Hierarchical Models

of ingestion, as compared to repeatedly sampled patients which had not taken apixaban prior
to the study. Therefore, c0, j,1 = 0

∀ j. The quantity c0, j,2 can be estimated from the other

pharmacokinetic parameters assuming subjects have been taking apixaban twice daily with
perfect adherence for the last 5 days. This can be done by solving the associated differential
equation with the Laplace Transform.
Each pharmacokinetic parameter has an associated set of regression coefficients and intercept term. Each pharmacokinetic parameter is regressed on subject covariates x j,s in the
following way:
log(Cl j,s ) = µCl + xCl
j,s βCl

(6.1)

log(tmax, j,s ) = µt + xtj,s βt

(6.2)

logit(α j,s ) = µα + xαj,s βα

(6.3)

logit(F j,s ) = µF + xFj,s βF

(6.4)

Here, we have added superscripts to the x to indicate that different covariates may be used
in each regression. The β are regression coefficients and µ are intercepts for the parameter
indicated in the subscript. We include random effects for repeatedly sampled subjects. Each θ j,s
is used to predict the concentration profile C(t). We use a one compartment pharmacokinetic
model with first order elimination as our C(t), namely

!

D j,s F j,s ke, j,s ka, j,s −ka, j,s (ti −δ j,s )


−k
(t
−δ
)
e,
j,s
i
j,s

e
c +
−e
δ j,s ≤ ti


 0, j,s Cl j,s (ke, j,s − ka, j,s )
C j,s (ti ) = 





0
else
Again, if s = 1 (indicating repeated sampling) then c0, j,1 = 0

∀ j since patients from

this study take apixaban for the first time. If s = 2 (indicating sparse sampling) then δ j,2 is
assumed to be 0 ∀ j since the delay can not be estimated from a single observation. Finally, the
predicted latent concentrations are used in the likelihood. We use a lognormal likelihood for
both datasets, with variance differing by study
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Figure 6.1: Bayes net for our hierarchical apixaban pharmacokientics model. Here, β and
µ are regression coefficients and intercepts for the effects of covariates on pharmacokientic
parameters. The effects are assumed to apply to all studies, meaning that the effect of age
on time to max concentration (as an example) is the same for all studies. If protocols are
different between studies, then each study may have a different residual variance term σ2s . This
differing residual variance (on the log scale) is what prevents subjects from being considered
exchangeable between studies. When permuting the joint distribution of θ j,s , one needs to
keep track of which θ requires which σ, thus preventing the subjects from being considered
exchangeable.



yi, j,s ∼ Lognormal log(C j,s (ti )), σ s .

6.4

Results

The results from our simulation study are shown in figure 6.2. The precision of the estimate
of effect of concomitant drug use increases as the number of repeatedly sampled (and sparsely
sampled) patients increases. Shown in red are the sample means of the 10 runs (black dots).
On average we see a small amount of bias in the estimates. This is expected since the sparsity
inducing priors have the majority of their density in a small neighbourhood of 0, regularizing
effects towards 0. For purposes of discovery, these biases may be acceptable if the result is a
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Table 6.1: Descriptive statistics for repeatedly sampled and sparsely sampled data. Note, amiodarone is a CYP3A4 inhibitor. The study which generated repeatedly sampled data excluded
any patients whom were taking CYP3A4 inhibitors, so all patients in the repeatedly sampled
data are assigned a value of 0 for concomitant amiodarone.
Repeatedly Sampled Data

Sparsely Sampled Data

Overall

(N=36)

(N=401)

(N=437)

Age
Mean (SD)
49.8 (11.5)
Median [Min, Max] 50.0 [26.0, 70.0]

78.8 (9.43)
79.0 [47.0, 98.0]

76.4 (12.5)
79.0 [26.0, 98.0]

Weight (kg)
Mean (SD)
88.0 (24.4)
Median [Min, Max] 83.5 [54.7, 137]

85.6 (23.8)
81.6 [40.0, 221]

85.8 (23.8)
81.8 [40.0, 221]

Creatinine (micromol/L)
Mean (SD)
68.0 (12.5)
Median [Min, Max] 65.0 [50.0, 95.0]

105 (44.5)
92.0 [42.0, 316]

102 (43.9)
89.0 [42.0, 316]

Sex
female
male

178 (44.4%)
223 (55.6%)

201 (46.0%)
236 (54.0%)

16.2 (60.1)
0 [0, 400]

14.9 (57.7)
0 [0, 400]

23 (63.9%)
13 (36.1%)

Concomitant Amiodrone (mg/day)
Mean (SD)
0 (0)
Median [Min, Max] 0 [0, 0]

decrease in model variability.
When using real data, our model can accurately predict both repeatedly sampled and sparsely
sampled data. Shown in figure 6.3 is a log-log plot of predicted and actual concentrations for
both datasets. The model makes more accurate predictions for repeatedly sampled patients
(because it is able to estimate the random effect in each pharmacokinetic parameter). The apparent increase in prediction error for the sparsely sampled can be partially explained by the
absence of random effects for each patient. The within and between patient variation manifests
as measurement error solely, thus leading to lower predictive ability.
With a model for the pharmacokinetics of apixaban in hand, estimates of salient pharmacokinetic phenomena can be easily obtained. In figure 6.4, we use our model to estimate the
max concentration for the reference patient under different doses of amiodarone. Through our
model, we estimate concomitant amiodarone increases bioavailability, which in turn increases
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Figure 6.2: Results from our simulation study. Black dots represent the estimated effect of
a novel predictor. Red dots indicate the average estimate across the 10 repetitions. Data are
faceted by the number of repeatedly sampled patients. Smaller datasets show more bias towards
the null. This bias attenuates as sample size increases.
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Figure 6.3: Predicted vs observed concentrations for both datasets on the log scale. Note each
plot has a separate scale. Sparsely sampled data can not be predicted as accurately as the
repeatedly sampled data, due in part to the inability to estimate patient random effects in pharmacokinetic parameters. This additional variance left unexplained manifests as measurement
error.
max concentration. Shown in black is the expected max concentration conditioned on concomitant amiodarone dose, as well as 95% equal tailed posterior credible intervals.
Additionally, we contrast the pooled model’s estimates of covariate effects with estimates
from model’s fit to either the sparse or repeatedly sampled data. Marginal posterior densities
for the effects of covariates on the pharmacokientic parameters are shown in figure 6.5. In
most cases, the effects seem to have higher precision due to the increase in sample size, and
generally there is no large disagreement in either sign or magnitude of effect estimates.

6.5

Discussion

The Bayesian model we present pools information across studies which may differ in study
protocol. Doing so allows investigators to make use of all available data – be they from con-
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Figure 6.4: Estimated max concentration as a function of concomitant amiodarone for a reference patient. Concomitant amiodarone is estimated to increase apixaban bioavailability, thus
leading to an increase in max concentration. The uncertainty in the effect of concomitant amiodarone is propagated through to the estimate of max concentration. If max concentration is a
key quantity in decision making, propagation of this uncertainty is crucial.
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Figure 6.5: Estimated covariate effects from models fit to each dataset separately and the pooled
model.

6.5. Discussion

103

trolled studies, or arising from patient interactions in a personalized medicine clinic – to fine
tune pharmacokinetic models to populations of interest. However, this is just one possible
model out of a family of similar models. One extension worth mentioning is estimating heterogeneity of effects between studies. Our model assumes that for a given covariate, the effect
is the same in different studies; the effect of weight on the clearance rate is the same across
studies, for example. This need not be assumed, and it may be the case that allowing for heterogeneity of effects between study populations may help explain additional variation beyond
what measured covariates already explain. The extension to include heterogeneity of effect is
straightforward for our model, and would see an extended hierarchy considered where each β
and µ are generated from some further distribution with unknown parameters. We do not to
implement this extension because our data consists of only two studies, making inference on
the between study variability in effects difficult to estimate reliably.
To demonstrate how our model can be used to discover novel predictors of pharmacokientics, we included a simulation study in which we place a double exponential prior on a
potentially novel covariate’s effect on the bioavalability of the drug. The double exponential
prior acts as a sparsity inducing prior, pulling large effects towards 0 as the LASSO does.
Our simulation study showed that our model is able to estimate the effect of this novel covariate reliably, even in circumstances where only a small amount of data on repeatedly sampled
patients are available to investigators. The estimates are biased towards the null due to the
sparsity inducing prior. This bias attenuates with more data becoming available, and can also
change depending on prior hyperparameters. From an estimation perspective, although the estimates of the effects are biased, they may be better suited to predict population effects due to
this decrease in variability, similar to the phenomenon displayed by the James-Stein estimator
[101, 53]. We believe that since the primary goal of exploration is not to get very precise estimates, but to rather to discover new avenues for future research, the exchange of variance for
bias is not only acceptable but also preferable.
Finally, we applied our model in a case study of apixaban. We pooled data from two
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sources; one from a well controlled clinical study, and the other from an observational setting. We used a sparsity inducing prior to regularize estimates of the effect of concomitant
amiodarone on bioavailability of apixaban. Concomitant amiodarone’s effect on apixaban concentration has been previously studied [45], however that model is more descriptive whereas
our model is mechanistic (in so far as we model the pharmacokientics explicitly) and incorporates prior information from previous studies. The findings in our case study and previous work
agree; concomitant amiodarone is associated with an increase in apixaban concentrations. It is
difficult to evaluate if the magnitudes are similar, however, mainly because our model posits a
multiplicative effect whereas previous models assume an additive effect. However, our model
is capable of providing richer inferences due to the mechanistic model and fully Bayesian analysis. We can propagate uncertainty in the effect of concomitant amiodarone through to other
salient pharmacokinetic measures, like max concentration (see figure 6.4). Additionally, uncertainty in other pharmacokinetic measures can be propagated. For example, where as previous
models relied on a point estimate of time to max concentration – which was the same for each
subject – our model can estimate each patient’s time to max concentration (conditioned on
covariates) and uncertainty in that estimate propagates through to max concentration. The posterior distribution of max concentration then captures all uncertainty relevant to the decision,
meaning credible intervals should – at least in theory – also have better coverage for individuals. Though a similar Bayesian pharmacokinetic model could be fit using only the sparsely
sampled data, pooling information using repeatedly sampled data should be beneficial because
of the high precision in estimates of covariate effects afforded by the repeated sampling.
The marginal posterior distributions of the effects display behavior consistent with partially
pooled models. Models fit to each dataset could be considered as a non-pooled estimate, our
model – which combines information from multiple datasets – can be considered as a pooled
estimate. Partially pooled models have the effect of regularizing estimates towards the population mean, but the size of this regularization depends on the precision and magnitude of the
estimate. This behavior is most clearly shown in the radon example provided in chapter 12 of
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Gelman and Hill’s book on multilevel modelling [36]. Gelman and Hill describe an analysis
of exposure to radon – a known carcinogen in high concentrations – across 3000 counties in
the United States. Within each county, a variable number of houses were measured for radon
exposure. Importantly, some counties had more observations than others. Within each county,
an average level of radon exposure can be estimated. However, those counties with fewer observations have smaller precision in the estimate. Those counties with large effects and high
precision see little regularization in the estimate of average radon exposure when comparing
non-pooled estimates to pooled estimates. Those counties with large effects and small precision see a strong amount of regularization (see figure 12.1 in Gelman and Hill [36]). Similar
explanations can be applied to our model. As an example, we see that the effect of weight on
clearance (Cl in our model) has been regularized to be a compromise of the estimates obtained
from models fit on the repeatedly and sparsely sampled data separately. Additionally, we can
see that there is little regularization in effects where one dataset provides a high precision estimate (as in creatinine’s effect on clearance). The tendency for partially pooled models to
regularize towards the population mean has the effect of trading variance for bias, a theme that
has permeated this work. This should in principle result in estimates of the effects with smaller
root mean squared error.
Our study is not without limitations. Firstly, our repeatedly sampled data come from a
study concerning patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Some patients in
this study had NAFLD, others did not. Our sparsely sampled data did not collect this variable,
and so technically it should be considered missing. One strategy is to impute this variable, be
it though frequentist methods or Bayesian methods. We choose not to impute this and simply
exclude it from our model since the study which generated the repeatedly sampled data failed
to detect a statistically significant effect of NAFLD on apixaban pharmacokinetics [109]. Additionally, because patients in the sparsely sampled data were sampled only once, we were forced
to assume their time delay was 0. The time delay is most probably non-zero, and making this
assumption may increase the variability of estimates of other pharmacokientic measures. Fi-
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nally, the subjects in each study are quite different with subjects in the repeatedly sampled data
being younger, healthier, and with better kidney function on average. Since subjects in the
sparsely sampled data are generally different, a linear effect of covariates on pharmacokientic
parameters may not be appropriate due to extrapolation. A possible remedy for this would
be to model the effects of covariates using splines or other suitably flexible methods. If additional subject matter expertise is available, investigators may choose to model the effects
with monotone-splines. We believe specifications about the functional form of effects are best
done with the aid of subject matter experts (pharmacologists, physicians, etc) and opt for the
simplest non-trivial functional form for our effects.

6.6

Conclusion

In this study, we demonstrated how investigators could accomplish the goals of accurate modelling of pharmacokientics and exploration of new variables via the use of a heirarchical
Bayesian model of pharmacokientics. The model pools information from multiple studies and
shrinks estimates of effects. The result is a trade off of variance for bias, which should improve predictive accuracy. Additioanlly, we peformed a simulation study to demonstrate how
sparisty inducing priors can be used to indentify effects of new variables. We showed that, even
in small samples, a small amount of bias is observed in estimates of novel effects and this bias
attenuates with more data. Future research may include modelling heterogeneity of effect by
adding another level to the hierarchy.

Chapter 7
Discussion
This thesis contributes to the goals of identifying factors driving between patient variability in
drug response, and selecting the optimal dose for a patient. These problems were approached
from the context of pharmacokinetics, arguing that drivers of variability in concentrations may
be drivers of variability in response since concentration is a proxy for systematic exposure.
The first article presented a comparison of a population pharmacokinetic model fit using Maximum A Posteriori and Hamiltonian Monte Carlo for the purposes of decision making on dosing. Additionally, a one compartment pharmacokinetic model with first order elimination was
presented which leveraged a non-dimensionalization to force identifiability of the model and
facilitated use of Hamiltonian Monte Carlo for sampling from the posterior distribution. The
simulation studies from this article provided evidence that models fit using Hamiltonian Monte
Carlo resulted in better calibrated decisions when the goal is to select a dose to avoid the
risk of exceeding some concentration threshold. The second article provided a framework for
combining Bayesian pharmacokinetic models with dynamic treatment regimes for the comparison of various modes of personalization. A case study on apixaban was used demonstrate
the benefits of various forms of personalization and motivated conversation on if the benefits
would outweigh the burden placed on the patient to adhere to additional follow up. The final
article highlighted important violations of assumptions of exchangeability when combining
107

108

Chapter 7. Discussion

data from different studies and offered a model which satisfies those assumptions, allowing
investigators to combine all data available to them to perform inference on pharmacokinetic
models. Sparsity-inducing priors were also motivated as a means of determining if novel variables have an appreciable affect on pharmacokinetic measures, such as the drug bio availability.
The sparsity-inducing priors approach trades off variance for a small amount of bias and side
steps issues associated with variable selection, a common approach used in determining which
variables to include in a pharmacokinetic model.

7.1
7.1.1

Key Themes
On The Need To Simulate Plausible Data and Evaluate Models On
Their Intended Use

New advancements in statistical theory can take time to be adopted across disciplines. In
the case of HMC, theoretical understanding is still developing, but additional theoretical and
applied evidence for preferring HMC over MAP continues to mount. Though theoretical warnings for MAP’s deficiency were published earlier this decade, the first article in this thesis
demonstrated that deficiency could manifest in non-obvious ways for models important to personalized medicine. Indeed, models fit by HMC and MAP appeared to be equivalent when
compared on predictive accuracy, but decisions made therefrom were very different with different outcomes. MAP is motivated by low dimensional intuition — that because integrals are
linear operators, and density is largest around the mode, then the areas around the mode should
contribute most to expectations. The importance of intuition in statistics, and mathematical
modelling of any kind more broadly, can not be overstated. However, that intuition can fail
when dimensionality increases due to the so called “Curse of Dimensionality”.
The shift from “low” dimensionality where intuition is effective to “high” dimensionality
happens quickly. Modelling intuition needs to be validated, and that validation may not necessarily come directly from examining the fitted model (e.g. by examining the distribution
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of residuals). The importance of simulating plausible data from models with known ground
truth and fitting proposed models to that data is a known but often unreported approach to
model validation. This approach may not be necessary for all techniques (for example when
models are fit via optimization and the objective function is convex with unique optima, such
in the case of most generalized linear models), but for non-standard models or models which
are highly non-linear, it can be an effective tool for discovering hidden modelling pathologies.
Since the publication of the first article, additional research has been published on a “Bayesian
workflow” [39] in which fitting models to simulated data is listed as an explicit step. Often, the
inferences we wish to make go beyond that of parameter values, and plausible data simulation
can help in ensuring that the resulting model is capable of returning accurate inferences, or
discovering that the model as written is incapable of doing so.
Additionally, data simulation can provide evidence that the model may not be able to be
fit as it is written. While HMC is effective and efficient, modelling benefits do not come for
free. When models suffer from pathologies detectable from sampling diagnostics, the remedies
to those pathologies can be non-trivial. A standard implementation of the pharmacokinetic
model presented in the first article suffered from slow sampling times, and often chains failed
to converge to the same target distribution. Often, the key to an effective implementation
comes down to an effective parameterization, and this was the case for this model. The nondimensionalization offered a way to force identifiability of the model while also incorporating
high quality prior information, and the result was an efficient sampling with no detectable
pathologies.

7.1.2

On Diminishing Returns on Personalization and The Need to Incorporate Patient Preferences

Sequential decision making is an important aspect of personalized medicine. However, there
are sometimes in which sequential optimization is important, and others when it makes a negligible difference. The second article in this thesis provided a framework for evaluating different
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modes of personalization. In that article, sequentially optimal modes of personalization yielded
smaller regret on average than those which only used information from a single point in time.
However, the magnitude of that difference — at least in the case studies presented — were
small. The decision to implement one mode of personalization over another would thus also
need to consider costs (monetary or otherwise) associated with each mode. While the considerations for those decisions may vary from facility to facility, statistical methodology can help
to determine how much better one mode could perform over another in ideal circumstances.
Also, while personalized medicine may focus on the peculiarities of the individual patient,
there is also the need to incorporate patient preferences into the decision making process. As
Elliot et. al note, incorporating patient preferences and reducing the burden of personalization
on the patient can result in sustained adherence, thereby increasing effectiveness and further
preventing adverse events [31].

7.1.3

On The Need for Efficient Use of Data Resources in the Study of
Personalized Medicine

The observation that some drugs have variability in concentrations in excess of that observed in
clinical trials motivates the “fine tuning” of pharmacokinetic models to a population of interest.
However, the data resources available to pharmaceutical companies may not be realistic for
individual researchers or smaller institutions to obtain. Making use of data collected on the
same drug in different studies is one way to increase the data available for personalization. The
development of new methodologies and models to facilitate this combination is crucial, as the
models will likely have to account for individual study peculiarities. Those developments can
not happen in isolation and will require a collaboration between modellers and domain experts.
Investigators seeking to develop such new methods must be careful not to make simplifying assumptions which may threaten the internal validity of the inference. Previous models
studying the effects of various clinical factors on apixaban concentration were perhaps too sim-
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ple1 . The resulting inferences may have been valid from a statistical perspective, but could
lack useful interpretation in the applied domain depending on which questions are being asked
of the model. This provides an extreme example, and future research would likely be subject
to more nuanced challenges, such as the violation of exchangeability discussed in the third
article. Carefully navigating the modelling process will require collaboration with expert modellers. Those modellers must also be receptive to receiving feedback from domain experts, and
must work diligently to extract necessary information from those experts.

7.1.4

Future Work

The foundation of this work is the Bayesian pharmacokinetic model, hence additional effort
should be put into ensuring the model is of sufficient quality and aligns with expert knowledge. In particular, ensuring the priors reflect expert knowledge as accurately as possible is a
clear avenue for improvement. This work could take many forms, including a Bayesian meta
analysis to synthesize effects from various previous studies. Additionally, the problem of prior
elicitation from experts has spurred research in human computer interaction, resulting in interactive ways of evaluating the agreement of priors with expert knowledge [94]. Once priors
are agreed upon, the construction of a Bayesian model from the population of interest can be
performed. This thesis leveraged data from highly controlled clinical study for most modelling
efforts. A more heterogeneous sample may lead to better generalizability, and hence better
decisions made from said model. Further work could be done to refine inferences from the
measurement process too. If instruments are calibrated, using data from the calibration process
can provide useful information usable by the model.
The work presented in this thesis surrounding optimal sequential decision making used a
value function which was simple and easy to interpret. In reality, the reward function used
implicitly in the clinic is more complex and likely varies between clinicians. The dosing decisions made by clinicians offer the opportunity to learn the implied reward function and then use
1

I feel comfortable saying this because I was the one who recommended the approach [44].
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that function in a dynamic treatment regime. This would be an opportunity to apply inverse
reinforcement learning in which the agent learns a reward function which when maximized
produces actions consistent with the observed actions. Additionally, there is the opportunity to
explicitly incorporate health economic factors into the framework presented here for purposes
of comparing modes of personalization.
When combining data from different studies, it may be unlikely that all studies measure the
same variables. Work on Bayesian inference for missing variables could be used to extend the
work I presented in the third article. This can be accomplished in two ways. In the first, the
missing data are multiply imputed and a Bayesian model is fit to each multiply imputed dataset.
The posterior samples are then concatenated and treated as draws from some bigger model
which is thought to integrate over the uncertainty in the missing data. The second approach
is to jointly model the concentration data and the missing data. Both approaches would rely
on the assumption that the missingness is only associated with the variables collected and not
any unmeasured variables. Additionally, while the variables from well controlled studies are
likely high precision, those variables obtained from studies with less precision may benefit
from an “error in variables approach.” These approaches will undoubtedly add uncertainty to
the model, but honest uncertainty is likely preferable to exaggerated precision.

7.2

Conclusion

This thesis presented techniques for identifying factors driving variation in drug response and
optimal dose selection using Bayesian statistics and dynamic treatment regimes in conjunction
with pharmacokinetic models. Personalized medicine seeks to make better decisions for the
individual patient in light of high degrees of between patient variation in response. The contributions from this thesis are important in so far as they aid in the ability to make decisions.
Better decisions can come about through modelling which more honestly represents the resulting posterior distribution, as was evidenced in chapter 4. Better decisions can come about by
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taking a holistic understanding of personalization, which goes beyond clinical measurements
and accounts for burden. The work in chapter 4 laid the foundation for future work in this direction. Lastly, better decisions can come about by sharing data and making as efficient use of
that data as possible, as mentioned in chapter 6. That sharing of data will also require continued
collaborations between practitioners of different fields.
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